10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended October 29, 2022

or

☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___________ to ___________

Commission File Number 0-14818

KASPIEN HOLDINGS INC.

(Exact Name of Registrant as Specified in its Charter)

New York	14-1541629
State or Other Jurisdiction of Incorporation or Organization	I.R.S. Employer Identification No.
2818 N. Sullivan Rd. Ste 130 Spokane Valley, WA	99216
Address of Principal Executive Offices	Zip Code

(855) 300-2710

Registrant’s Telephone Number, Including Area Code

Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $.01 par value per share	KSPN	NASDAQ Stock Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes ☒    No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes ☒    No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer ☒	Smaller reporting company ☒
	Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐  

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).  Yes ☐     No ☒

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PRECEDING FIVE YEARS:

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.      Yes ☐    No ☐

APPLICABLE ONLY TO CORPORATE ISSUERS

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

Common Stock, $.01 par value,

4,964,753 shares outstanding as of December 10, 2022

Kaspien Holdings Inc.

KASPIEN HOLDINGS INC. AND SUBSIDIARIES

QUARTERLY REPORT ON FORM 10-Q

INDEX TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

	Form 10-Q Page No.
PART I. FINANCIAL INFORMATION
Item 1 – Interim Condensed Consolidated Financial Statements (Unaudited)
Condensed Consolidated Balance Sheets as of October 29, 2022, January 29, 2022 and October 30, 2021	4
Condensed Consolidated Statements of Operations – Thirteen Weeks and Thirty-nine Weeks Ended October 29, 2022 and October 30, 2021	5
Condensed Consolidated Statements of Comprehensive Loss – Thirteen Weeks and Thirty-nine Weeks Ended October 29, 2022 and October 30, 2021	6
Condensed Consolidated Statements of Shareholders’ Equity – Thirteen and Thirty-nine Weeks Ended October 29, 2022 and October 30, 2021	7
Condensed Consolidated Statements of Cash Flows – Thirty-nine Weeks Ended October 29, 2022 and October 30, 2021	8
Notes to Interim Condensed Consolidated Financial Statements	9
Item 2 – Management’s Discussion and Analysis of Financial Condition and Results of Operations	22
Item 3 – Quantitative and Qualitative Disclosures about Market Risk	30
Item 4 – Controls and Procedures	30
PART II.  OTHER INFORMATION
Item 1 – Legal Proceedings	31
Item 1A – Risk Factors	31
Item 2 – Unregistered Sales of Equity Securities and Use of Proceeds	31
Item 3 – Defaults Upon Senior Securities	31
Item 4 – Mine Safety Disclosures	31
Item 5 – Other Information	32
Item 6 – Exhibits	32
Signatures	33

2

FORWARD-LOOKING STATEMENTS

This quarterly report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, particularly in the discussion under the caption “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” All statements other than statements of historical fact are forward-looking. Examples of forward-looking statements include, but are not limited to, statements regarding our ability to achieve profitability and meet future liquidity needs and capital requirements, future business, future results of operations or financial condition, our business strategies and the COVID-19 pandemic. You can identify many forward-looking statements by words such as “may,” “will,” “would,” “should,” “could,” “expect,” “aim,” “anticipate,” “believe,” “estimate,” “intend,” “plan,” “predict,” “project,” “seek,” “potential,” “opportunities” and other similar expressions and the negatives of such expressions. However, not all forward-looking statements contain these words. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from those expressed or implied by the forward-looking statements contained herein. Such risks and uncertainties include, among others, those risks discussed under the caption “Risk Factors” in our most recently filed Annual Report on Form 10‑K, which was filed with the Securities and Exchange Commission (the “SEC”) on April 29, 2022 (the “2022 Form 10-K”), and in our consolidated financial statements, related notes, and the other information appearing elsewhere in the 2022 Form 10‑K, this quarterly report on Form 10-Q and our other filings with the SEC. Given these risks and uncertainties, you should not place undue reliance on any forward-looking statements. The forward-looking statements contained in this quarterly report on Form 10-Q are made only as of the date hereof, and we do not intend, and, except as required by law, we undertake no obligation to update any forward-looking statements contained herein after the date of this report to reflect actual results or future events or circumstances.

3

KASPIEN HOLDINGS INC. AND SUBSIDIARIES

PART 1. FINANCIAL INFORMATION

Item 1 - Interim Condensed Consolidated Financial Statements

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except per share and share amounts)

(unaudited)

	October 29,			January 29,			October 30,
	2022			2022			2021
ASSETS	Unaudited						Unaudited
CURRENT ASSETS
Cash and cash equivalents	$	769		$	1,218		$	1,754
Restricted cash		1,158			1,158			1,158
Accounts receivable		2,796			2,335			2,566
Merchandise inventory		37,353			29,277			30,248
Prepaid expenses and other current assets		706			649			760
Total current assets		42,782			34,637			36,486
Restricted cash		1,601			2,447			2,732
Fixed assets, net		2,140			2,335			2,251
Operating lease right-of-use assets		1,678			2,144			2,284
Cash Surrender Value		3,563			4,154			4,413
Other assets		682			965			1,074
TOTAL ASSETS	$	52,446		$	46,682		$	49,240
LIABILITIES
CURRENT LIABILITIES
Accounts payable	$	12,648		$	6,271		$	6,743
Short-term borrowings		9,494			9,966			5,858
Accrued expenses and other current liabilities		1,962			2,362			2,685
Current portion of operating lease liabilities		634			649			636
Total current liabilities		24,738			19,248			15,922
Operating lease liabilities		1,253			1,608			1,764
Long-term debt		9,163			4,356			4,161
Other long-term liabilities		13,590			14,185			15,515
TOTAL LIABILITIES		48,744			39,397			37,362
SHAREHOLDERS’ EQUITY
Preferred stock  ($0.01 par value; 5,000,000 shares authorized; none issued)		-			-			-
Common stock ($0.01 par value; 200,000,000 shares authorized; 5,321,985, 3,902,985 and 3,902,985 shares issued, respectively)		53			39			39
Additional paid-in capital		213,992			359,220			359,100
Treasury stock at cost (467,069, 1,410,378 and 1,410,378 shares, respectively)		(76,132	)		(230,170	)		(230,170	)
Accumulated other comprehensive loss		(910	)		(910	)		(2,007	)
Accumulated deficit		(133,301	)		(120,894	)		(115,084	)
TOTAL SHAREHOLDERS’ EQUITY		3,702			7,285			11,878
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$	52,446		$	46,682		$	49,240

See Accompanying Notes to Interim Condensed Consolidated Financial Statements.

4

KASPIEN HOLDINGS INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(amounts in thousands)

(unaudited)

	Thirteen Weeks Ended						Thirty-nine Weeks Ended
	October 29,			October 30,			October 29,			October 30,
	2022			2021			2022			2021
Net revenue	$	29,145		$	32,172		$	94,843		$	107,680
Cost of sales		22,570			24,168			74,688			81,044
Gross profit		6,575			8,004			20,155			26,636
Selling, general and administrative expenses		9,255			10,018			29,975			30,886
Loss from operations		(2,680	)		(2,014	)		(9,820	)		(4,250	)
Interest expense		881			439			2,544			1,455
Other income		-			(1,567	)		-			(3,530	)
Loss before income tax expense		(3,561	)		(886	)		(12,364	)		(2,175	)
Income tax expense		-			-			43			46
Net loss	$	(3,561	)	$	(886	)	$	(12,407	)	$	(2,221	)
BASIC AND DILUTED LOSS PER SHARE:
Basic and diluted loss per common share	$	(0.92	)	$	(0.36	)	$	(4.15	)	$	(0.92	)
Weighted average number of common shares outstanding – basic and diluted		3,865			2,491			2,990			2,404

See Accompanying Notes to Interim Condensed Consolidated Financial Statements.

5

KASPIEN HOLDINGS INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(amounts in thousands)

(unaudited)

	Thirteen Weeks Ended						Thirty-nine Weeks Ended
	October 29,			October 30,			October 29,			October 30,
	2022			2021			2022			2021
Net loss	$	(3,561	)	$	(886	)	$	(12,407	)	$	(2,221	)
Amortization of pension gain		-			-			-			-
Comprehensive loss	$	(3,561	)	$	(886	)	$	(12,407	)	$	(2,221	)

See Accompanying Notes to Interim Condensed Consolidated Financial Statements.

6

KASPIEN HOLDINGS INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY

(dollars and shares in thousands)

	Thirteen Weeks Ended October 29, 2022
	Number of shares outstanding													Accumulated			Retained
								Additional			Treasury			Other			Earnings
	Common		Treasury			Common		Paid-in			Stock			Comprehensive			(Accumulated			Shareholders’
	Shares		Shares			Stock		Capital			At Cost			Loss			Deficit)			Equity
Balance as of July 30, 2022		3,912		(772	)	$	39	$	263,723		$	(125,906	)	$	(910	)	$	(129,740	)	$	7,206
Net loss		-		-			-		-			-			-			(3,561	)		(3,561	)
Issuance of shares, net of expenses		-		-			-		-			-			-			-			-
Exercise of warrants		1,403		305			14		(49,788	)		49,774			-			-			-
Common stock issued-Restricted share units		7		-			-		1			-			-			-			1
Amortization of unearned compensation/restricted stock amortization		-		-			-		57			-			-			-			57
Balance as of October 29, 2022		5,322		(467	)	$	53	$	213,992		$	(76,132	)	$	(910	)	$	(133,301	)	$	3,702

	Thirty-Nine Weeks Ended October 29, 2022
	Number of shares outstanding													Accumulated			Retained
								Additional			Treasury			Other			Earnings
	Common		Treasury			Common		Paid-in			Stock			Comprehensive			(Accumulated			Shareholders’
	Shares		Shares			Stock		Capital			At Cost			Loss			Deficit)			Equity
Balance as of January 29, 2022		3,903		(1,410	)	$	39	$	359,220		$	(230,170	)	$	(910	)	$	(120,894	)	$	7,285
Net loss		-		-			-		-			-			-			(12,407	)		(12,407	)
Issuance of shares, net of expenses		-		638			-		(97,127	)		104,264			-			-			7,137
Issuance of warrants		-		-			-		1,518			-			-			-			1,518
Exercise of warrants		1,403		305			14		(49,788	)		49,774			-			-			-
Vested restricted of shares		7		-			-		1			-			-			-			1
Common stock issued- Director grants		9		-			-		41			-			-			-			41
Amortization of unearned compensation/restricted stock amortization		-		-			-		128			-			-			-			128
Balance as of October 29, 2022		5,322		(467	)	$	53	$	213,992		$	(76,132	)	$	(910	)	$	(133,301	)	$	3,702

	Thirteen Weeks Ended October 30, 2021
	Number of shares outstanding												Accumulated			Retained
								Additional		Treasury			Other			Earnings
	Common		Treasury			Common		Paid-in		Stock			Comprehensive			(Accumulated			Shareholders’
	Shares		Shares			Stock		Capital		At Cost			Loss			Deficit)			Equity
Balance as of July 31, 2021		3,903		(1,410	)	$	39	$	359,016	$	(230,170	)	$	(2,007	)	$	(114,198	)	$	12,680
Net loss		-		-			-		-		-			-			(886	)		(886	)
Amortization of unearned compensation/restricted stock amortization		-		-			-		84		-			-			-			84
Balance as of October 30, 2021		3,903		(1,410	)	$	39	$	359,100	$	(230,170	)	$	(2,007	)	$	(115,084	)	$	11,878

	Thirty-Nine Weeks Ended October 30, 2021
	Number of shares outstanding												Accumulated			Retained
								Additional		Treasury			Other			Earnings
	Common		Treasury			Common		Paid-in		Stock			Comprehensive			(Accumulated			Shareholders’
	Shares		Shares			Stock		Capital		At Cost			Loss			Deficit)			Equity
Balance as of January 30, 2021		3,337		(1,410	)	$	33	$	346,495	$	(230,169	)	$	(2,007	)	$	(112,863	)	$	1,489
Net loss		-		-			-		-		-			-			(2,221	)		(2,221	)
Issuance of warrants		138		-			2		-		(1	)		-			-			1
Sales of shares, net of expense		417		-			4		12,227		-			-			-			12,231
Exercise of stock options		2		-			-		51		-			-			-			51
Common stock issued- Director grants		9		-			-		184		-			-			-			184
Amortization of unearned compensation/restricted stock amortization		-		-			-		143		-			-			-			143
Balance as of October 30, 2021		3,903		(1,410	)	$	39	$	359,100	$	(230,170	)	$	(2,007	)	$	(115,084	)	$	11,878

See Accompanying Notes to Interim Condensed Consolidated Financial Statements.

7

KASPIEN HOLDINGS INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(amounts in thousands)

(unaudited)

	Thirty-nine Weeks Ended
	October 29,			October 30,
	2022			2021
OPERATING ACTIVITIES:
Net loss	$	(12,407	)	$	(2,221	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of fixed assets		961			1,064
Amortization of intangible assets		-			732
Stock-based compensation		169			327
Amortization of ROU asset		466			458
Amortization of warrant interest		766			191
Interest on long term debt		849			570
Change in cash surrender value		591			(557	)
Forgiveness of PPP Loan		-			(1,963	)
Changes in operating assets and liabilities that provide (use) cash:
Accounts receivable		(461	)		150
Merchandise inventory		(8,075	)		(5,732	)
Prepaid expenses and other current assets		(56	)		(196	)
Other long-term assets		283			268
Accounts payable		6,377			(2,150	)
Accrued expenses and other current liabilities		(706	)		236
Other long-term liabilities		(951	)		(1,167	)
Net cash used in operating activities		(12,194	)		(9,990	)
INVESTING ACTIVITIES:
Purchases of fixed assets		(766	)		(1,046	)
Net cash provided by (used in) investing activities		(766	)		(1,046	)
FINANCING ACTIVITIES:
Proceeds from long term borrowings		5,000			-
Proceeds from issuance of shares, net of expense		7,137			12,231
Proceeds from exercise of stock options		-			51
Payments of PPP loan		-			(76	)
Payment of short term borrowings		(9,966	)		(6,339	)
Payments of long term borrowings		-			(1,600	)
Proceeds from short term borrowings		9,494			5,858
Net cash provided by (used in) financing activities		11,665			10,125
Net increase (decrease) in cash, cash equivalents, and restricted cash		(1,295	)		(911	)
Cash, cash equivalents, and restricted cash, beginning of period		4,823			6,555
Cash, cash equivalents, and restricted cash, end of period	$	3,528		$	5,644
Supplemental disclosures and non-cash investing and financing activities:
Interest paid	$	461		$	295
Warrants issued with debt	$	1,633		$	-

See Accompanying Notes to Interim Condensed Consolidated Financial Statements.

8

KASPIEN HOLDINGS INC. AND SUBSIDIARIES

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

October 29, 2022 and October 30, 2021

Note 1. Nature of Operations

Kaspien Holdings Inc., which, together with its consolidated subsidiaries, is referred to herein as “Kaspien”, “the Company”, “we”, “us” and “our”, was incorporated in New York in 1972. We own 100% of the outstanding common stock of Kaspien Inc, through which our principal operations are conducted. Kaspien provides a platform of software and services to empower brands to grow their online distribution channels on digital marketplaces such as Amazon, Walmart, Target, eBay, among others. The Company helps brands achieve their online retail goals through its innovative and proprietary technology, tailored strategies, and mutually beneficial partnerships.

Kaspien provides a platform of software and services to empower brands to grow their online distribution channels on digital marketplaces such as Amazon, Walmart and Target, among others. The Company helps brands achieve their online retail goals through its innovative and proprietary technology, tailored strategies and mutually beneficial partnerships.

We are guided by 5 core principles:

• We are partner obsessed. Our customers are our partners. Every decision is focused on building mutually beneficial relationships that deliver results.

• We are insights driven. We make data actionable. Our curiosity drives us to discover opportunities early and often.

• We create simplicity. We challenge the status quo. We take the complicated and simplify it.

• We take ownership. We make things happen. We hold ourselves accountable and have a bias for action.

• We empower each other. We welcome and learn from diverse experiences. Our empathy ignites innovation and empowers meaningful change.

Liquidity and Cash Flows:

The Company’s primary sources of liquidity are its borrowing capacity under its Credit Facility, available cash and cash equivalents, and to a lesser extent, cash generated from operations. Our cash requirements relate primarily to working capital needed to operate Kaspien, including funding operating expenses, the purchase of inventory and capital expenditures.

The Company incurred a net loss of $12.4 million and $2.2 million for the thirty-nine weeks ended October 29, 2022 and October 30, 2021, respectively.  The increase in the net loss was primarily attributable to a decrease in sales and gross margin. In addition, the Company has an accumulated deficit of $133.3 million as of October 29, 2022 and net cash used in operating activities for the thirty-nine weeks ended October 29, 2022 was $12.2 million. Net cash used in operating activities for the thirty-nine weeks ended October 30, 2021 was $10.0 million.

As disclosed in the Company’s Annual Report on Form 10-K filed April 29, 2022, the Company experienced negative cash flows from operations during fiscal 2021 and 2020 and we expect to incur net losses in fiscal 2022.

9

Our ability to achieve profitability and meet future liquidity needs and capital requirements will depend upon numerous factors, including the timing and amount of our revenue; the timing and amount of our operating expenses; the timing and costs of working capital needs; successful implementation of our strategy and planned activities; and our ability to overcome the impact of the COVID-19 pandemic. There can be no assurance that we will be successful in further implementing our business strategy or that the strategy, including the completed initiatives, will be successful in sustaining acceptable levels of sales growth and profitability. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.

The unaudited condensed consolidated financial statements for the thirteen and thirty-nine weeks ended October 29, 2022 were prepared pursuant to the rules and regulations of the Securities and Exchange Commission. The information furnished in these unaudited condensed consolidated financial statements reflects all normal, recurring adjustments which, in the opinion of management, are necessary for the fair presentation of such financial statements. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The ability of the Company to meet its liabilities and to continue as a going concern is dependent on improved profitability, the strategic initiatives for Kaspien and the availability of future funding. Based on recurring losses from operations, negative cash flows from operations, the expectation of continuing operating losses for the foreseeable future, and uncertainty with respect to any available future funding, the Company has concluded that there is substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

As of October 29, 2022, we had cash and cash equivalents of $0.8 million, net working capital of $18.0 million, and $9.5 in borrowings on our revolving credit facility, as further discussed below.

As of January 29, 2022, the Company had borrowings of $10.0 million under the Credit Facility. As of October 29, 2022 and October 30, 2021, the Company had no outstanding letters of credit. The Company had $5.2 million and $10.9 million available for borrowing under the Credit Facility as of October 29, 2022 and October 30, 2021, respectively.

On March 18, 2021, the Company closed an underwritten offering of 416,600 shares of common stock of the Company, at a price to the public of $32.50 per share. The gross proceeds of the offering were approximately $13.5 million, prior to deducting underwriting discounts and commissions and estimated offering expenses. The Company used the net proceeds from the offering for general corporate purposes, including working capital to implement its strategic plans, investments in technology to enhance its scalable platform and its core retail business.

Credit Facility

On February 20, 2020, Kaspien Inc. entered into a Loan and Security Agreement (as subsequently amended, the “Loan Agreement”) with Eclipse Business Capital LLC (f/k/a Encina Business Credit, LLC) (“Eclipse”), as administrative agent, under which the lenders party thereto committed to provide up to $25 million in loans under a four-year, secured revolving credit facility (the “Credit Facility”).

10

On March 30, 2020, the Company and Kaspien Inc. (the “Loan Parties”) entered into Amendment No. 1 to the Loan Agreement (the “Amendment”). Pursuant to the Amendment, among other things, (i) the Company was added as “Parent” under the Amended Loan Agreement, (ii) the Company granted a first priority security interest in substantially all of the assets of the Company, including inventory, accounts receivable, cash and cash equivalents and certain other collateral, and (iii) the Loan Agreement was amended to (a) permit the incurrence of certain subordinated indebtedness under the Subordinated Loan Agreement (as defined below) and (b) limit the Company’s ability to incur additional indebtedness, create liens, make investments, make restricted payments or specified payments and merge or acquire assets.

On April 7, 2021, the Loan Parties entered into Amendment No. 2 to the Loan Agreement (the “Second Amendment”. Pursuant to the Second Amendment, the In-Transit Inventory Sublimit (as defined in the Loan Agreement) was increased from $2,000,000 to $2,500,000.

On September 17, 2021, the Loan Parties entered into Amendment No. 3 to the Loan Agreement (the “Third Amendment”). Pursuant to the Third Amendment, among other things, (i) the maturity of the Credit Facility has been extended to February 20, 2024, and the early termination fees have been accordingly reset; (ii) the LIBOR floor has been reduced to 1.00%; (iii) up to $4,000,000 of acquisitions are now allowed without Eclipse’s consent, subject to satisfaction of various conditions, including the Company having a trailing twelve month fixed charge coverage ratio of 1.20x and Excess Availability greater than the greater of (x) 20% of the average Borrowing Base for each 30 day period immediately prior to, and pro forma for, the purchase and (y) $1,500,000.

On March 2, 2022, the Loan Parties entered into Amendment No. 4 to the Loan Agreement (the “Fourth Amendment”). Pursuant to the Fourth Amendment, among other things, the Credit Facility was amended to permit the incurrence of the Additional Subordinated Loan (as defined below) under the Subordinated Loan Agreement (as defined below).

On November 1, 2022, the Loan Parties entered into Amendment No. 5 to the loan agreement (the “Fifth Amendment”). Pursuant to the Fifth Amendment, the Credit Facility was amended to replace LIBOR with the Secured Overnight Funding Rate (“SOFR”).

As of October 29, 2022 and October 30, 2021, the Company had borrowings of $9.5 and $5.9 million under the Credit Facility, respectively.

Subordinated Debt Agreement

On March 30, 2020, the Loan Parties entered into a Subordinated Loan and Security Agreement (the “Subordinated Loan Agreement”) with the lenders party thereto from time to time (the “Lenders”) and TWEC Loan Collateral Agent, LLC (the “Collateral Agent”), as collateral agent for the Lenders, pursuant to which the Lenders made a $5.2 million secured term loan (the “Subordinated Loan”) to Kaspien with a scheduled maturity date of May 22, 2023. As of October 29, 2022, unamortized debt issuance costs of $0.1 million are included in “Long Term Debt” on the unaudited condensed consolidated balance sheet.

Directors Jonathan Marcus, Thomas Simpson, and Michael Reickert are the chief executive officer of Alimco Re Ltd. (“Alimco”), the managing member of Kick-Start III, LLC and Kick-Start IV, LLC (“Kick-Start”), and a trustee of the Robert J. Higgins TWMC Trust (the “Trust”), an affiliate of RJHDC, LLC (“RJHDC” and together with Alimco and Kick-Start, “Related Party Entities”), respectively.  The Related Party Entities are parties to the Subordinated Loan Agreement.

Amendment No. 2 to Subordinated Loan and Security Agreement

On March 2, 2022, the Loan Parties entered into that certain Amendment No. 2 to Subordinated Loan and Security Agreement (“Amendment No. 2”) with the “Lenders and the Collateral Agent. Pursuant to Amendment No. 2, among other things, Alimco Re Ltd. (the “Tranche B Lender”) made an additional $5,000,000 secured term loan (the “Additional Subordinated Loan”) with a scheduled maturity date of March 31, 2024, which is the same maturity date as the existing loans under the Subordinated Loan Agreement.

11

Interest on the Additional Subordinated Loan accrues, subject to certain terms and conditions under the Subordinated Loan Agreement, at the rate of fifteen percent (15.0%) per annum, compounded on the last day of each calendar quarter by becoming a part of the principal amount of the Additional Subordinated Loan.

The Additional Subordinated Loan is also secured by a second priority security interest in substantially all of the assets of the Loan Parties, including inventory, accounts receivable, cash and cash equivalents and certain other collateral of the borrowers and guarantors under the Subordinated Loan Agreement. The Company will provide a limited guarantee of Kaspien’s obligations under the Additional Subordinated Loan.

Among other things, the Subordinated Loan Agreement limits the Loan Parties’ ability to incur additional indebtedness, create liens, make investments, make restricted payments or specified payments and merge or acquire assets.

The Subordinated Loan Agreement contains customary events of default, including, but not limited to, payment defaults, breaches of representations and warranties, covenant defaults, cross-defaults to other obligations, customary ERISA defaults, certain events of bankruptcy and insolvency, judgment defaults, the invalidity of liens on collateral, change in control, cessation of business or the liquidation of material assets of the borrowers and guarantors thereunder taken as a whole and the occurrence of an uninsured loss to a material portion of collateral.

The Loan Parties paid certain customary fees and expenses in connection with the Additional Subordinated Loan and Amendment No. 2.

Paycheck Protection Program

On April 17, 2020, Kaspien received loan proceeds of $2.0 million (the “PPP Loan”) pursuant to the Paycheck Protection Program (“PPP”) under the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”). On June 14, 2021, the Small Business Administration (“SBA”) approved the Company’s application for forgiveness of the PPP Loan. The amount of the forgiveness was $1.9 million in principal and interest, which was the amount requested in the forgiveness application and was less than the original principal balance due of $2.0 million. Following the grant of forgiveness, an outstanding balance of $76,452 was paid during fiscal 2021.

In addition to the aforementioned current sources of existing working capital, the Company may explore certain other strategic alternatives that may become available to the Company, as well continuing our efforts to generate additional sales and increase margins. However, at this time the Company has no commitments to obtain any additional funds, and there can be no assurance such funds will be available on acceptable terms or at all, should we require such additional funds. If the Company is unable to improve its operations, it may be required to obtain additional funding, and the Company’s financial condition and results of operations may be materially adversely affected.

Furthermore, broad market and industry factors may seriously harm the market price of our common stock, regardless of our operating performance, and may adversely impact our ability to raise additional funds, should we require such additional funds.

Impact of COVID-19

The full extent to which the COVID-19 pandemic will continue to directly or indirectly impact our business, results of operations and financial condition, including expenses, reserves and allowances, and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19, including the actions taken to contain or treat it, as well as the economic impact on local, regional, national and international customers and markets, which are highly uncertain and cannot be predicted at this time. Our leadership team believes we have the necessary controls in place to mitigate these impacts.

12

Note 2. Basis of Presentation

The accompanying interim condensed consolidated financial statements consist of Kaspien Holdings Inc., its wholly owned subsidiaries, Kaspien NY, LLC (f/k/a Trans World NY Sub, Inc. (f/k/a Record Town, Inc.)) and its subsidiaries, and Kaspien, Inc. All intercompany accounts and transactions have been eliminated.

The interim condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. The information furnished in these unaudited interim condensed consolidated financial statements reflects all normal, recurring adjustments which, in the opinion of management, are necessary for the fair presentation of such financial statements. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of net revenue and expenses during the reporting period. Actual results could differ from those estimates. Certain information and footnote disclosures normally included in the financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to rules and regulations applicable to interim financial statements.

The accompanying unaudited interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto and Management’s Discussion and Analysis of Financial Condition and Results of Operations as of and for the year ended January 29, 2022 contained in the Company’s Annual Report on Form 10-K filed April 29, 2022.  The results of operations for the thirteen and thirty-nine weeks ended October 29, 2022 are not necessarily indicative of the results to be expected for the entire fiscal year ending January 28, 2023.

The Company’s significant accounting policies are the same as those described in Note 1 to the Company’s Consolidated Financial Statements on Form 10-K for the fiscal year ended January 29, 2022.

Note 3. Recently Adopted Accounting Pronouncements

In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,” which introduced an expected credit loss model for the impairment of financial assets measured at amortized cost. The model replaces the probable, incurred loss model for those assets and instead, broadens the information an entity must consider in developing its expected credit loss estimate for assets measured at amortized cost. This standard will be effective for smaller reporting companies for fiscal years beginning after December 15, 2022, however early adoption is permitted. We are currently evaluating the impact of this new standard on the consolidated financial statements.

13

In March 2020, the FASB issued ASU No. 2020-04, “Reference Rate Reform (Topic 848): facilitation of the Effects of Reference Rate Reform on Financial Reporting” (“ASU 2020-04”). ASU 2020-04 provides optional expedients and exceptions for applying U.S. GAAP to contract modifications and hedging relationships that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. ASU 2020-04 provides, among other things, guidance that modifications of contracts within the scope of Topic 470, Debt, should be accounted for by prospectively adjusting the effective interest rate; modifications of contracts within the scope of Topic 840, Leases, should be accounted for as a continuation of the existing contract; and, changes in the critical terms of hedging relationships, caused by reference rate reform, should not result in the de-designation of the instrument, provided certain criteria are met. The Company’s exposure to LIBOR rates includes its credit facility. The amendments are effective as of March 12, 2020 through December 31, 2022. Adoption is permitted at any time. The Company is currently evaluating the impact this update will have on its Condensed Consolidated Financial Statements.

Recent accounting pronouncements pending adoption not discussed above are either not applicable or are not expected to have a material impact on our consolidated financial condition, results of operations, or cash flows.

Note 4. Intangible Assets

The determination of the fair value of intangible assets acquired in a business acquisition, including the Company’s acquisition of Kaspien in 2016, is subject to many estimates and assumptions. Our identifiable intangible assets that resulted from our acquisition of Kaspien consist of  technology and tradenames. As of October 30, 2021, the intangible assets were fully amortized. Amortization expense of intangible assets for the thirteen and thirty-nine weeks ended October 29, 2022 and October 30, 2021 consisted of the following:

	Thirteen Weeks Ended				Thirty-nine Weeks Ended
	October 29,		October 30,		October 29,		October 30,
(amounts in thousands)	2022		2021		2022		2021
Amortized intangible assets:
Technology	$	-	$	65	$	-	$	259
Trade names and trademarks		-		153		-		473
Total amortization expense	$	-	$	218	$	-	$	732

Note 5. Depreciation and Amortization

Depreciation and amortization included in selling, general and administrative expenses of the interim condensed consolidated statements of operations for the thirteen weeks ended October 29, 2022 and October 30, 2021 was $0.4 million and $0.6 million, respectively.

Depreciation and amortization included in selling, general and administrative expenses of the interim condensed consolidated statements of operations for the thirty-nine weeks ended October 29, 2022 and October 30, 2021 was $1.0 million and $1.8 million, respectively.

Note 6. Restricted Cash

As a result of the death of its former Chairman, the Company holds $2.8 million in a rabbi trust, of which $1.2 million is classified as restricted cash in current assets and $1.6 million is classified as restricted cash in other assets on the accompanying interim condensed consolidated balance sheet as of October 29, 2022.

A summary of cash, cash equivalents and restricted cash is as follows (amounts in thousands):

	October 29,		January 29,		October 30,
	2022		2022		2021
Cash and cash equivalents	$	769	$	1,218	$	1,754
Restricted cash		2,759		3,605		3,890
Total cash, cash equivalents and restricted cash	$	3,528	$	4,823	$	5,644

Note 7.  Debt

Credit Facility

On February 20, 2020, Kaspien Inc. entered into a Loan and Security Agreement (as subsequently amended, the “Loan Agreement”) with Eclipse Business Capital LLC (f/k/a Encina Business Credit, LLC) (“Eclipse”), as administrative agent, under which the lenders party thereto committed to provide up to $25 million in loans under a four-year, secured revolving credit facility (the “Credit Facility”).

The commitments by the lenders under the Credit Facility are subject to borrowing base and availability restrictions. Up to $5.0 million of the Credit Facility may be used for the making of swing line loans.

Interest under the Credit Facility accrues, subject to certain terms and conditions under the Loan Agreement, at a LIBOR Rate or Base Rate, plus, in each case, an Applicable Margin, which is determined by reference to the level of Availability as defined in the Loan Agreement, with the Applicable Margin for LIBOR Rate loans ranging from 4.00% to 4.50% and the Applicable Margin for Base Rate loans ranging from 3.00% to 3.50%.

The Credit Facility is secured by a first priority security interest in substantially all of the assets of Kaspien, including inventory, accounts receivable, cash and cash equivalents and certain other collateral of the borrowers and guarantors under the Credit Facility (collectively, the “Credit Facility Parties”) and by a first priority pledge by the Company of its equity interests in Kaspien. The Company will provide a limited guarantee of Kaspien’s obligations under the Credit Facility.

Among other things, the Loan Agreement limits Kaspien’s ability to incur additional indebtedness, create liens, make investments, make restricted payments or specified payments and merge or acquire assets. The Loan Agreement also requires Kaspien to comply with a financial maintenance covenant.

The Loan Agreement contains customary events of default, including, but not limited to, payment defaults, breaches of representations and warranties, covenant defaults, cross-defaults to other obligations, customary ERISA defaults, certain events of bankruptcy and insolvency, judgment defaults, the invalidity of liens on collateral, change in control, cessation of business or the liquidation of material assets of the Credit Facility Parties taken as a whole, the occurrence of an uninsured loss to a material portion of collateral and failure of the obligations under the Credit Facility to constitute senior indebtedness under any applicable subordination or intercreditor agreements.

On March 30, 2020, the Company and Kaspien (the “Loan Parties”) entered into Amendment No. 1 to the Loan Agreement (the “Amendment”). Pursuant to the Amendment, among other things, (i) the Company was added as “Parent” under the Amended Loan Agreement, (ii) the Company granted a first priority security interest in substantially all of the assets of the Company, including inventory, accounts receivable, cash and cash equivalents and certain other collateral, and (iii) the Loan Agreement was amended to (a) permit the incurrence of certain subordinated indebtedness under the Subordinated Loan

14

Agreement (as defined below) and (b) limit the Company’s ability to incur additional indebtedness, create liens, make investments, make restricted payments or specified payments and merge or acquire assets.

On April 7, 2021, Loan Parties entered into Amendment No. 2 to the Loan Agreement (the “Second Amendment”. Pursuant to the Second Amendment, the In-Transit Inventory Sublimit (as defined in the Loan Agreement) was increased from $2,000,000 to $2,500,000.

On September 17, 2021, the Loan Parties entered into Amendment No. 3 to the Loan Agreement (the “Third Amendment”). Pursuant to the Third Amendment, among other things, (i) the maturity of the credit facility has been extended to February 20, 2024, and the early termination fees have been accordingly reset; (ii) the LIBOR floor has been reduced to 1.00%; (iii) up to $4,000,000 of acquisitions are now allowed without Eclipse’s consent, subject to satisfaction of various conditions, including the Company having a trailing twelve month fixed charge coverage ratio of 1.20x and Excess Availability greater than the greater of (x) 20% of the average Borrowing Base for each 30 day period immediately prior to, and pro forma for, the purchase and (y) $1,500,000.

On March 2, 2022, the Loan Parties entered into Amendment No. 4 to the Loan Agreement (“Fourth Amendment”). Pursuant to the Fourth Amendment, among other things, the Credit Facility was amended to permit the incurrence of the Additional Subordinated Loan (as defined below) under the Subordinated Loan Agreement (as defined below).

On November 1, 2022, the Loan Parties entered into Amendment No. 5 to the Loan Agreement (the “Fifth Amendment”). Pursuant to the Fifth Amendment, the Credit Facility was amended to replace LIBOR with the Secured Overnight Funding Rate (“SOFR”).

As of October 29, 2022, the Company had borrowings of $9.5 million under the Credit Facility. The Company had borrowings of $5.9 million as of October 30, 2021. As of October 29, 2022, unamortized debt issuance costs of $0.1 million related to the Credit Facility are included in Other assets on the unaudited condensed consolidated balance sheet.

The Company records short term borrowings at cost, in which the carrying value approximates fair value due to its short-term maturity.

Subordinated Loan Agreement

On March 30, 2020, the Loan Parties entered into a Subordinated Loan and Security Agreement (the “Subordinated Loan Agreement”) with the lenders party thereto from time to time (the “Lenders”) and TWEC Loan Collateral Agent, LLC (the “Collateral Agent”), as collateral agent for the Lenders, pursuant to which the Lenders made a $5.2 million secured term loan (the “Subordinated Loan”) to Kaspien. On September 17, 2021, the Loan Parties entered into Amendment No. 1 to the Subordinated Loan Agreement which extended the maturity of the loan to March 31, 2024. As of October 29, 2022, unamortized debt issuance costs of $0.1 million are included in “Long-Term Debt” on the consolidated balance sheet.

Interest on the Subordinated Loan accrues, subject to certain terms and conditions under the Subordinated Loan Agreement, at the rate of twelve percent (12.0%) per annum, compounded on the last day of each calendar quarter by becoming a part of the principal amount of the Subordinated Loan.

The Subordinated Loan is secured by a second priority security interest in substantially all of the assets of the Loan Parties, including inventory, accounts receivable, cash and cash equivalents and certain other collateral of the borrowers and guarantors under the Subordinated Loan Agreement (collectively, the “Second Lien Credit Facility Parties”). The Company will provide a limited guarantee of Kaspien ’s obligations under the Subordinated Loan.

15

Among other things, the Subordinated Loan Agreement limits the Loan Parties’ ability to incur additional indebtedness, create liens, make investments, make restricted payments or specified payments and merge or acquire assets.

The Subordinated Loan Agreement contains customary events of default, including, but not limited to, payment defaults, breaches of representations and warranties, covenant defaults, cross-defaults to other obligations, customary ERISA defaults, certain events of bankruptcy and insolvency, judgment defaults, the invalidity of liens on collateral, change in control, cessation of business or the liquidation of material assets of the Second Lien Credit Facility Parties taken as a whole and the occurrence of an uninsured loss to a material portion of collateral.

In conjunction with the Subordinated Debt Agreement, the Company issued warrants to purchase up to 244,532 shares of Common Stock to the Related Party Entities (127,208 shares for Alimco, 23,401 shares for Kick-Start, and 93,923 shares for RJHDC), subject to adjustment in accordance with the terms of the Warrants, at an exercise price of $0.01 per share. As of October 29, 2022, 7,539 warrants remain outstanding.

The value of the warrants of $0.7 million was allocated against the principal proceeds of the Subordinated Debt Agreement, $0.2 million of which was unamortized as of October 29, 2022.

On March 2, 2022, the Loan Parties entered into that certain Amendment No. 2 to Subordinated Loan and Security Agreement (“Amendment No. 2”) the “Lenders and Collateral Agent. Pursuant to Amendment No. 2, among other things, Alimco Re Ltd. (the “Tranche B Lender”) made an additional $5,000,000 secured term loan (the “Additional Subordinated Loan”) with a scheduled maturity date of March 31, 2024, which is the same maturity date as the existing loans under the Subordinated Loan Agreement.

Interest on the Additional Subordinated Loan accrues, subject to certain terms and conditions under the Subordinated Loan Agreement, at the rate of fifteen percent (15.0%) per annum, compounded on the last day of each calendar quarter by becoming a part of the principal amount of the Additional Subordinated Loan.

The Additional Subordinated Loan is also secured by a second priority security interest in substantially all of the assets of the Loan Parties, including inventory, accounts receivable, cash and cash equivalents and certain other collateral of the borrowers and guarantors under the Subordinated Loan Agreement. The Company will provide a limited guarantee of Kaspien’s obligations under the Additional Subordinated Loan.

Among other things, the Subordinated Loan Agreement limits the Loan Parties’ ability to incur additional indebtedness, create liens, make investments, make restricted payments or specified payments and merge or acquire assets.

The Subordinated Loan Agreement contains customary events of default, including, but not limited to, payment defaults, breaches of representations and warranties, covenant defaults, cross-defaults to other obligations, customary ERISA defaults, certain events of bankruptcy and insolvency, judgment defaults, the invalidity of liens on collateral, change in control, cessation of business or the liquidation of material assets of the borrowers and guarantors thereunder taken as a whole and the occurrence of an uninsured loss to a material portion of collateral.

16

In conjunction with the Subordinated Debt Agreement, the Company issued warrants to purchase up to warrants to purchase up to 320,000 shares of common stock of the Company (subject to adjustment in accordance with the terms of the Warrants, the “Warrant Shares”) at an exercise price of $0.01 per share.  The Warrants are exercisable during the period commencing on March 2, 2022 and ending on the earlier of (a) 5:00 p.m. Eastern Standard Time on the five (5)-year anniversary thereof, or if such day is not a business day on the next succeeding business day, or (b) the occurrence of certain consolidations, mergers or similar extraordinary events involving the Company. As of October 29, 2022, all of the warrants remain outstanding.

The value of the warrants of $1.6 million was allocated against the principal proceeds of the Subordinated Debt Agreement, of which $1.1 million was unamortized as of October 29, 2022. The value of the warrants was recognized as a discount based on the relative fair value of the consideration received, as an offset to APIC, which will be amortized over the life of the loan.

Paycheck Protection Program

On April 17, 2020, Kaspien received loan proceeds of $2.0 million (the “PPP Loan”) pursuant to the Paycheck Protection Program (“PPP”) under the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”). On June 14, 2021, the Small Business Administration (“SBA”) approved the Company’s application for forgiveness of the PPP Loan. The amount of the forgiveness was $1.9 million in principal and interest, which was the amount requested in the forgiveness application and was less than the original principal balance due of $2.0 million. Following the grant of forgiveness, an outstanding balance of $76,452 was paid during fiscal 2021.

Note 8. Stock Based Compensation

The Company has outstanding awards under three employee stock award plans, the 2005 Long Term Incentive and Share Award Plan, the Amended and Restated 2005 Long Term Incentive and Share Award Plan (the “Old Plans”); and 2005 Long Term Incentive and Share Award Plan, as amended and restated on August 2, 2022 (the “New Plan”). Collectively, these plans are referred to herein as the Stock Award Plans. The Company no longer issues stock options under the Old Plans.

Equity awards authorized for issuance under the New Plan total 500,000. As of October 29, 2022, of the awards authorized for issuance under the Stock Award Plans, 70,364 options were granted and are outstanding, 25,294 of which were vested and exercisable. Shares available for future grants of options and other share-based awards under the New Plan as of October 29, 2022 were 497,000.

The following table summarizes stock award activity during the thirteen weeks ended October 29, 2022:

	Employee Stock Award Plans
	Number of Shares Subject To Option			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term		Other Share Awards (1)			Weighted Average Grant Fair Value
Balance January 29, 2022		85,965		$	13.41		7.5		90,000		$	15.39
Granted		21,750			5.57		9.9		9,000			4.59
Forfeited		(20,045	)		9.31		9.1		(63,500	)		14.08
Canceled		(17,306	)		15.56		-		-			-
Exercised		-			-		-		(12,000	)		10.77
Balance October 29, 2022		70,364		$	10.23		7.6		23,500		$	17.69
Exercisable October 29, 2022		25,294		$	18.70		6.2		-		$	-

 ⁽¹⁾ Other Share Awards include restricted share units granted to employees and directors.

As of October 29, 2022, the intrinsic value of stock awards outstanding and stock awards exercisable was $0.

17

Note 9. Shareholders’ Equity

On July 12, 2022, the Company entered into a Securities Purchase Agreement (the “PIPE Purchase Agreement”) with a single institutional investor for a private placement offering (“Private Placement”) of the Company’s common stock (the “Common Stock”) or pre-funded warrants, with each pre-funded warrant exercisable for one share of Common Stock (the “Pre-Funded Warrants”), and warrants exercisable for one share of Common Stock (the “Investor Warrants”). Pursuant to the PIPE Purchase Agreement, the Company has agreed to issue and sell 1,818,182 shares (the “Shares”) of its Common Stock or Pre-Funded Warrants in lieu thereof together with Investor Warrants to purchase up to 2,457,160 shares of Common Stock. Each share of Common Stock and accompanying Investor Warrant will be sold together at a combined offering price of $3.30 per share.

The Pre-Funded Warrants are immediately exercisable, at a nominal exercise price of $0.001, and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full.

The Investor Warrants have an exercise price of $3.13 per share (subject to adjustment as set forth in the warrant), are exercisable upon issuance and will expire five years from the date of issuance. The Investor Warrants contain standard adjustments to the exercise price including for stock splits, stock dividend, rights offerings and pro rata distributions.

The Private Placement closed on July 14, 2022. The Company received approximately $6 million in gross proceeds from the Private Placement, before deducting discounts and commissions and estimated offering expenses. The Company intends to use the net proceeds from the private placement for working capital and other general corporate purposes.

On July 12, 2022, the Company also entered into a Securities Purchase Agreement (the “Registered Purchase Agreement”) with a single institutional investor, pursuant to which the Company agreed to issue and sell 638,978 shares (the “Registered Shares”) of its Common Stock or Pre-Funded Warrants in lieu thereof, with each Pre-Funded Warrant exercisable for one share of Common Stock (the “Offering”). The Company received approximately $2 million in gross proceeds from the Offering, before deducting discounts and commissions and estimated offering expenses. The Company intends to use the net proceeds from the private placement for working capital and other general corporate purposes.

The Pre-Funded Warrants are immediately exercisable, at a nominal exercise price of $0.001, and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. As of October 29, 2022 109,416 Pre-Funded Warrants related to the Offering remain outstanding.

Net proceeds from the Private Placement and the Offering, after deducting placement agent fees and other estimated offering expenses payable by the Company of $0.9 million, were approximately $7.1 million.

The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company, all of which were exercisable, as of October 29, 2022:

Exercise		Number
Price		Outstanding
$	0.001		109,416
$	0.01		327,539
$	0.125		2,457,160
			2,894,115

18

Note 10. Accumulated Other Comprehensive Loss

Accumulated other comprehensive loss that the Company reports in the interim condensed consolidated balance sheets represents net loss, adjusted for the difference between the accrued pension liability and accrued benefit cost, net of taxes, associated with the Company’s defined benefit plan. Comprehensive loss consists of net loss for all periods presented.

Note 11. Defined Benefit Plan

The Company maintains a non-qualified Supplemental Executive Retirement Plan (“SERP”) for certain executive officers of the Company.  The SERP provides eligible executives defined pension benefits that supplement benefits under other retirement arrangements.  As of February 28, 2020, no active employees were participants in the SERP. During the thirteen weeks ended October 29, 2022, the Company did not make any cash contributions to the SERP and presently expects to pay approximately $1.2 million in benefits relating to the SERP during fiscal 2022.

The measurement date for the SERP is the fiscal year end, using actuarial techniques which reflect estimates for mortality, turnover and expected retirement. In addition, management makes assumptions concerning future salary increases. Discount rates are generally established as of the measurement date using theoretical bond models that select high-grade corporate bonds with maturities or coupons that correlate to the expected payouts of the applicable liabilities.

The following represents the components of the net periodic pension cost related to the Company’s SERP for the respective periods:

	Thirteen Weeks Ended				Thirty-nine Weeks Ended
(amounts in thousands)	October 29,		October 30,		October 29,		October 30,
	2022		2021		2022		2021
Interest cost	$	89	$	63	$	267	$	189
Net periodic pension cost	$	89	$	63	$	267	$	189

Note 12. Basic and Diluted Loss Per Share

Basic loss per share is calculated by dividing net loss by the weighted average common shares outstanding for the period. Diluted loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock (net of any assumed repurchases) that then shared in the earnings of the Company, if any.  It is computed by dividing net loss by the sum of the weighted average shares outstanding and additional common shares that would have been outstanding if the dilutive potential common shares had been issued for the Company’s common stock awards from the Company’s Stock Award Plans.

For the thirteen- and thirty-nine-week periods ended October 29, 2022 and October 30, 2021, the impact of all outstanding stock awards was not considered because the Company reported net losses in those periods and such impact would be anti-dilutive.  Accordingly, basic and diluted loss per share was the same. Total anti-dilutive stock awards for the thirteen and thirty-nine weeks ended October 29, 2022 were approximately 0.1 million shares.

For the thirteen-week and thirty-nine periods ended October 29, 2022, the impact of all outstanding warrants was not considered because the Company reported net losses in both periods and such impact would be anti-dilutive.  Accordingly, basic and diluted loss per share was the same. Total anti-dilutive warrants for the thirteen- and thirty -nine week periods ended October 29, 2022 were approximately 2.9 million shares.

19

Note 13. Income Taxes

In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized.  The ultimate realization of deferred tax assets is dependent on the generation of future taxable income. Management considers the scheduled reversal of taxable temporary differences, projected future taxable income and tax planning strategies in making this assessment.  Based on available objective evidence, management concluded that a full valuation allowance should continue to be recorded against the Company’s deferred tax assets. Management will continue to assess the need for and amount of the valuation allowance against the deferred tax assets by considering all available evidence to the Company’s ability to generate future taxable income in its conclusion of the need for a full valuation allowance.  Any reversal of the Company’s valuation allowance will favorably impact its results of operations in the period of reversal.  The Company is currently unable to determine whether or when that reversal might occur, but it will continue to assess the realizability of its deferred tax assets and will adjust the valuation allowance if it is more likely than not that all or a portion of the deferred tax assets will become realizable in the future.  The Company has significant net operating loss carry forwards and other tax attributes that are available to offset projected taxable income and current taxes payable, if any, for the year ending January 29, 2022.  The deferred tax impact resulting from the utilization of the net operating loss carry forwards and other tax attributes will be offset by a reduction in the valuation allowance. As of January 29, 2022, the Company had a net operating loss carry forward of $352.7 million for federal income tax purposes and approximately $214.4 million for state income tax purposes that expire at various times through 2040 and are subject to certain limitations and statutory expiration periods.  The Company has not changed its overall conclusion with respect to the need for a valuation allowance against its net deferred tax assets, which remain fully reserved.

Note 14. Commitments and Contingencies

Legal Proceedings

The Company is subject to legal proceedings and claims that have arisen in the ordinary course of its business and have not been finally adjudicated.  Although there can be no assurance as to the ultimate disposition of these matters, it is management’s opinion, based upon the information available at this time, that the expected outcome of these matters, individually and in the aggregate, will not have a material adverse effect on the results of operations and financial condition of the Company. As a result, the liability for the cases listed below is remote.

On June 18, 2021, Vijuve Inc. filed a lawsuit against Kaspien Inc. in the United States District Court for the Eastern District of Washington (Case No. 2:21-cv-00192-SAB) concerning a Retailer Agreement that the parties entered into in September of 2020. Vijuve manufactures skin care products and face massagers. The parties agreed that Kaspien would sell Vijuve’s products on Amazon. The complaint alleged that Kaspien breached the Retailer Agreement when it declined to acquiesce to Vijuve’s demand that Kaspien purchase over $700,000 of products. In total, Vijuve is seeking $774,000 in damages. Kaspien denies that it breached the agreement. Moreover, on July 19, 2021, Kaspien filed counterclaims and alleged that Vijuve breached the contract, including by refusing to buy back inventory from Kaspien upon termination of the Retailer Agreement.  Kaspien subsequently filed additional counterclaims against Vijuve for fraud and negligent misrepresentation. Kaspien is seeking at least $229,000 from Vijuve. A trial on all of the parties’ claims is scheduled for September 18, 2023. There is no determination of outcome, thus no contingencies are recognized as of the reporting date.

On February 17, 2022, CA Washington, LLC (“CA”) filed a lawsuit against Kaspien, Inc. in Wake County, North Carolina Superior Court (court file 22 CVS 2051). CA Washington, LLC claims that Kaspien, Inc. breached the contract between the parties by using CA’s technology platform to facilitate sales by third parties and by using CA’s technology to develop a competing platform. The lawsuit also includes an alternative claim for unjust enrichment and a claim for breach of North Carolina’s Unfair and Deceptive Trade Practices Act. CA seeks an unspecified amount of damages. Kaspien removed the lawsuit to federal court in the Eastern District of North Carolina (case number 5:22-cv-00111), filed an Answer denying CA’s claims, and asserted a counterclaim against CA for breach of contract and breach of the covenant of good faith and fair dealing. There is no determination of outcome, thus no contingencies are recognized as of the reporting date.

20

Contingent Value Rights

On March 30, 2020, the Company entered into the Contingent Value Rights Agreement (the “CVR Agreement”), pursuant to which the Related Party Entities received contingent value rights (“CVRs”) representing the contractual right to receive cash payments from the Company in an amount equal, in the aggregate, to 19.9% of the proceeds (10.35% for Alimco, 1.90% for Kick-Start, and 7.64% for RJHDC) received by the Company in respect of certain intercompany indebtedness owing to it by Kaspien and/or its equity interest in Kaspien. The Company does not anticipate these contingencies being met in Fiscal 2022.

On March 2, 2022, the Company entered into a Contingent Value Rights Agreement (the “Second CVR Agreement”) with the Tranche B Lender under the Subordinated Loan Agreement, pursuant to which the Tranche B Lender received contingent value rights (“Second CVRs”) representing the contractual right to receive cash payments from the Company in an amount equal, in the aggregate, to 9.0% of the proceeds received by the Company in respect of certain distributions by the Company or Kaspien; recapitalizations or financings of the Company or Kaspien (with appropriate carve out for trade financing in the ordinary course); repayment of intercompany indebtedness owing to the Company by Kaspien; or sale or transfer of any stock of the Company or Kaspien.

The CVRs terminate upon the earlier to occur of (i) certain consolidations, mergers or similar extraordinary events involving Kaspien (and, if applicable, the making of a cash payment by the Company to the Lenders pursuant to the CVR Agreement in connection therewith) and (ii) March 2, 2032.

21

KASPIEN HOLDINGS INC. AND SUBSIDIARIES

PART 1. FINANCIAL INFORMATION

Item 2 - Management’s Discussion and Analysis of Financial Condition and

Results of Operations

October 29, 2022 and October 30, 2021

Overview

Management’s Discussion and Analysis of Financial Condition and Results of Operations provides information that the Company’s management believes necessary to achieve an understanding of its financial statements and results of operations.  To the extent that such analysis contains statements which are not of a historical nature, such statements are forward-looking statements, which involve risks and uncertainties.  These risks include, but are not limited to, changes in the competitive environment, availability of new products, change in vendor policies or relationships, general economic factors in markets where the Company’s merchandise is sold, and other factors discussed in the Company’s filings with the Securities and Exchange Commission.  The following discussion and analysis of the Company’s financial condition and results of operations should be read in conjunction with the unaudited interim condensed consolidated financial statements and related notes included elsewhere in this report and the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K as of and for the fiscal year ended January 29, 2022.

Kaspien provides a platform of software and services to empower brands to grow their online distribution channels on digital marketplaces such as Amazon, Walmart and Target, among others. The Company helps brands achieve their online retail goals through its innovative and proprietary technology, tailored strategies and mutually beneficial partnerships.

We are guided by 5 core principles:

• We are partner obsessed. Our customers are our partners. Every decision is focused on building mutually beneficial relationships that deliver results.

• We are insights driven. We make data actionable. Our curiosity drives us to discover opportunities early and often.

• We create simplicity. We challenge the status quo. We take the complicated and simplify it.

• We take ownership. We make things happen. We hold ourselves accountable and have a bias for action.

• We empower each other. We welcome and learn from diverse experiences. Our empathy ignites innovation and empowers meaningful change.

The Company’s results have been, and will continue to be, contingent upon management’s ability to understand industry trends and to manage the business in response to those trends and general economic trends. Management monitors several key performance indicators to evaluate its performance, including:

Net Revenue:  The Company measures total year over year sales growth. The Company measures its sales performance through several key performance indicators including number of partners, active product listings and sales per listing.

Cost of Sales and Gross Profit:  Gross profit is calculated based on the cost of product in relation to its retail selling value. Changes in gross profit are impacted primarily by net sales levels, mix of products sold, obsolescence, distribution costs, and Amazon commissions and fulfillment fees.

22

Gross Merchandise Value (“GMV”): The total value of merchandise sold over a given time period through a customer-to-customer exchange site. It is the measurement of merchandise value sold across all channels and partners within our platform.

Selling, General and Administrative (“SG&A”) Expenses:  Included in SG&A expenses are payroll and related costs, occupancy charges, general operating and overhead expenses and depreciation charges.

Balance Sheet and Ratios:  The Company views cash and working capital (current assets less current liabilities) as relevant indicators of its financial position.  See Liquidity and Cash Flows section for further discussion of these items.

RESULTS OF OPERATIONS

Thirteen Weeks Ended October 29, 2022

Compared to the Thirteen Weeks Ended October 30, 2021

Net revenue and Gross profit.  The following table sets forth a year-over-year comparison of the Company’s Net revenue and Gross profit:

	Thirteen Weeks Ended						Change					Thirty-Nine Weeks Ended						Change
(amounts in thousands)	October 29, 2022			October 30, 2021			$			%		October 29, 2022			October 30, 2021			$			%
Net Revenue	$	29,145		$	32,172		$	(3,027	)	-9.4	%	$	94,843		$	107,680		$	(12,837	)	-11.9	%
Gross profit		6,575			8,004			(1,429	)	-17.9	%		20,155			26,636			(6,481	)	-24.3	%
% to sales		22.6	%		24.9	%							21.3	%		24.7	%

Net Revenue. Net revenue was $29.1 million for the thirteen weeks ended October 29, 2022 a 9.4% decrease from the comparable prior year period. Net revenue was $94.8 million for the thirty-nine weeks ended October 29, 2022 a 11.9% decrease from the comparable prior year period.

The primary source of revenue is the Retail as a Service (“RaaS”) model, which represented 96% of net revenue in the thirteen weeks ended October 29, 2022. The Company generates revenue across a broad array of product lines primarily through the Amazon Marketplace. Categories include apparel, baby, beauty, electronics, health & personal care, home/kitchen/grocery, pets, sporting goods, toys & art.

Total active partner count as of October 29, 2022 was approximately 150, including 132 retail partners and 18 subscription partners.

Platform GMV for the three months ended October 29, 2022 was $63.9 million as compared to $63.5 million for the three months ended October 30, 2021.  Retail GMV decreased 7.8% to $30.4 million compared to $33.0 million in the comparable year-ago period. Subscription GMV increased 9.7% to $33.5 million, or 52.4% of total GMV, compared to $30.5 million, or 47.6% of total GMV, in the comparable year-ago period.

23

	Thirteen weeks ended											Thirty-nine weeks ended
	October 29, 2022				October 30, 2021				Change			October 29, 2022				October 30, 2021				Change
Amazon US	$	27,883	95.7	%	$	30,423	94.6	%		-8.3	%	$	89,480	94.3	%	$	100,581	93.4	%		-11.0	%
Amazon International		528	1.8	%		738	2.3	%		-28.5	%		2,807	3.0	%		4,295	4.0	%		-34.6	%
Other Marketplaces		350	1.2	%		543	1.7	%		-35.5	%		1,131	1.2	%		1,428	1.3	%		-20.8	%
Subtotal Retail as a Service		28,761	98.7	%		31,704	98.5	%		-9.3	%		93,418	98.5	%		106,304	98.7	%		-12.1	%
Subscriptions		384	1.3	%		468	1.5	%		-17.9	%		1,425	1.5	%		1,376	1.3	%		3.6	%
Net revenue	$	29,145	100.0	%	$	32,172	100.0	%		-9.4	%	$	94,843	100.0	%	$	107,680	100.0	%		-11.9	%

Gross Profit. The following table sets forth a period over period comparison of the Company’s gross profit:

	Thirteen Weeks Ended						Change					Thirty-nine Weeks						Change
(amounts in thousands)	October 29, 2022			October 30, 2021			$			%		October 29, 2022			October 30, 2021			$			%
Merchandise margin	$	12,691		$	14,653		$	(1,962)		-13.4	%	$	40,858		$	49,309		$	(8,451)		-17.1	%
% of net revenue		43.5	%		45.5	%		-2.0	%				43.1	%		45.8	%		-2.7	%
Fulfillment fees		(3,888	)		(4,375	)		487		-11.1	%		(13,110	)		(16,218	)		3,108		-19.2	%
Warehousing and freight		(2,228	)		(2,274	)		46		-2.0	%		(7,593	)		(6,455	)		(1,138)		17.6	%
Gross profit	$	6,575		$	8,004		$	(1,429)		-17.9	%	$	20,155		$	26,636		$	(6,481)		-24.3	%
% of net revenue		22.6	%		24.9	%							21.3	%		24.7	%

Gross profit was $6.6 million for the thirteen weeks ended October 29, 2022, as compared to $8.0 million for the comparable prior year period. The decrease in gross profit was primarily attributable to a reduction in net revenue on the Amazon US Platform and a decrease in merchandise margin. Gross profit as a percentage of net revenue for the thirteen weeks ended October 29, 2022 was 22.6% as compared to 24.9% for the thirteen weeks ended October 30, 2021. Merchandise margin for the thirteen-week period ending October 29, 2022 was 43.5% as compared to 45.5% for the comparable prior year period.

Gross profit for the thirty-nine weeks ended October 29, 2022 was $20.2 million, or 21.3% of net revenue, as compared to $26.6 million, or 24.7% of net revenue for the comparable prior year period as increased net revenue was offset by higher warehousing and freight expenses.

SG&A Expenses.  The following table sets forth a period over period comparison of the Company’s SG&A expenses:

	Thirteen Weeks Ended						Change					Thirty-Nine Weeks Ended						Change
(amounts in thousands)	October 29, 2022			October 30, 2021			$			%		October 29, 2022			October 30, 2021			$			%
Selling expenses	$	4,206		$	4,580		$	(374	)	-8.2	%	$	13,683		$	15,571		$	(1,888	)	-12.1	%
General and administrative expenses		5,049			5,438			(389	)	-7.2	%		16,292			15,315			977		6.4	%
Total SG&A expenses	$	9,255		$	10,018		$	(763	)	-7.6	%	$	29,975		$	30,886		$	(911	)	-2.9	%
As a % of total revenue		31.8	%		31.1	%							31.6	%		28.7	%

For the thirteen weeks ended October 29, 2022, SG&A expenses were $9.3 million as compared to $10.0 million for the prior year period. Selling expenses decreased $0.4 million for the thirteen weeks ended October 29, 2022 as compared to the prior year period. General and administrative expenses decreased $0.4 million for the thirteen weeks ended October 29, 2022.

24

Consolidated depreciation and amortization expense for the thirteen weeks ended October 29, 2022 was $0.4 million as compared to $0.6 million for the comparable prior year period.

For the thirty-nine weeks ended October 29, 2022, SG&A were $30.0 million as compared to $30.9 million for the comparable prior year period. Selling expenses decreased $1.9 million for the thirty-nine weeks ended October 29, 2022. General and administrative expenses increased $1.0 million for the thirty-nine weeks ended October 30, 2021.

Consolidated depreciation and amortization expense for the thirty-nine weeks ended October 30, 2021 was $1.0 million as compared to $1.8 million for the comparable prior year period.

Interest Expense.   Interest expense was $0.9 million for the thirteen weeks ended October 29, 2022 compared to $0.4 million for the thirteen weeks ended October 30, 2021.  The increase in interest expense was due to increased short and long-term borrowings.

Interest expense was $2.5 million for the thirty-nine weeks ended October 29, 2022 compared to $1.5 million for the thirty-nine weeks ended October 30, 2021.  The increase in interest expense was due to increased short and long-term borrowings.  See Note 7 to the Condensed Consolidated Financial Statements for further detail on the Company’s debt.

Income Tax Expense.   Based on available objective evidence, management concluded that a full valuation allowance should be recorded against the Company's deferred tax assets  As a result, there were insignificant tax expense amounts recorded during the thirteen weeks ended October 29, 2022 and October 30, 2021.

Net Loss. The net loss for the thirteen weeks ended October 29, 2022 was $3.6 million as compared to a net loss of $0.9 million for the comparable prior year period.

LIQUIDITY

Liquidity and Cash Flows:

The Company’s primary sources of liquidity are its borrowing capacity under its Credit Facility, available cash and cash equivalents, and to a lesser extent, cash generated from operations. Our cash requirements relate primarily to working capital needed to operate Kaspien, including funding operating expenses, the purchase of inventory and capital expenditures. Our ability to achieve profitability and meet future liquidity needs and capital requirements will depend upon numerous factors, including the timing and amount of our revenue; the timing and amount of our operating expenses; the timing and costs of working capital needs; successful implementation of our strategy and planned activities; and our ability to overcome the impact of the COVID-19 pandemic.

The Company incurred a net loss of $12.4 million and $2.2 million for the thirty-nine weeks ended October 29, 2022 and October 30, 2021, respectively.  The increase in the net loss was primarily attributable to a decrease in sales and gross margin. In addition, the Company has an accumulated deficit of $133.3 million as of October 29, 2022 and net cash used in operating activities for the thirty-nine weeks ended October 29, 2022 was $12.2 million. Net cash used in operating activities for the thirty-nine weeks ended October 30, 2021 was $10.0 million.

As disclosed in the Company's Annual Report on Form 10-K filed April 29, 2022, the Company experienced negative cash flows from operations during fiscal 2021 and 2020 and we expect to incur net losses in fiscal 2022.

25

Our ability to achieve profitability and meet future liquidity needs and capital requirements will depend upon numerous factors, including the timing and amount of our revenue; the timing and amount of our operating expenses; the timing and costs of working capital needs; successful implementation of our strategy and planned activities; and our ability to overcome the impact of the COVID-19 pandemic. There can be no assurance that we will be successful in further implementing our business strategy or that the strategy, including the completed initiatives, will be successful in sustaining acceptable levels of sales growth and profitability. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.

The unaudited condensed consolidated financial statements for the thirteen weeks ended October 29, 2022 were prepared pursuant to the rules and regulations of the Securities and Exchange Commission. The information furnished in these unaudited condensed consolidated financial statements reflects all normal, recurring adjustments which, in the opinion of management, are necessary for the fair presentation of such financial statements. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The ability of the Company to meet its liabilities and to continue as a going concern is dependent on improved profitability, the strategic initiatives for Kaspien and the availability of future funding. Based on recurring losses from operations, negative cash flows from operations, the expectation of continuing operating losses for the foreseeable future, and uncertainty with respect to any available future funding, the Company has concluded that there is substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

As of January 29, 2022, the Company had borrowings of $10.0 million under the Credit Facility. As of October 29, 2022 and October 30, 2021, the Company had no outstanding letters of credit. The Company had $5.2 million and $10.9 million available for borrowing under the Credit Facility as of October 29, 2022 and October 30, 2021, respectively.

On March 18, 2021, the Company closed an underwritten offering of 416,600 shares of common stock of the Company, at a price to the public of $32.50 per share. The gross proceeds of the offering were approximately $13.5 million, prior to deducting underwriting discounts and commissions and estimated offering expenses. The Company used the net proceeds from the offering for general corporate purposes, including working capital to implement its strategic plans, investments in technology to enhance its scalable platform and its core retail business.

On July 12, 2022, the Company entered into a Securities Purchase Agreement (the “PIPE Purchase Agreement”) with a single institutional investor for a private placement offering (“Private Placement”) of the Company’s common stock (the “Common Stock”) or pre-funded warrants, with each pre-funded warrant exercisable for one share of Common Stock (the “Pre-Funded Warrants”), and warrants exercisable for one share of Common Stock (the “Investor Warrants”). Pursuant to the PIPE Purchase Agreement, the Company has agreed to issue and sell 1,818,182 shares (the “Shares”) of its Common Stock or Pre-Funded Warrants in lieu thereof together with Investor Warrants to purchase up to 2,457,160 shares of Common Stock. Each share of Common Stock and accompanying Investor Warrant will be sold together at a combined offering price of $3.30 per share.

26

The Pre-Funded Warrants are immediately exercisable, at a nominal exercise price of $0.001, and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. As of October 29, 2022 109,416 Pre-Funded Warrants related to the Offering remain outstanding.

The Investor Warrants have an exercise price of $3.13 per share (subject to adjustment as set forth in the warrant), are exercisable upon issuance and will expire five years from the date of issuance. The Investor Warrants contain standard adjustments to the exercise price including for stock splits, stock dividend, rights offerings and pro rata distributions.

The Private Placement closed on July 14, 2022. The gross proceeds to the Company from the Private Placement, after deducting placement agent fees and other estimated offering expenses payable by the Company, were approximately $7.1 million. The Company intends to use the net proceeds from the private placement for working capital and other general corporate purposes.

27

The following table sets forth a summary of key components of cash flow and working capital:

			As of or for the Thirty-nine Weeks Ended						Change
	(amounts in thousands)		October 29, 2022			October 30, 2021			$
	Operating Cash Flows		$	(12,193	)	$	(9,990	)	$	(2,203	)
	Investing Cash Flows			(766	)		(1,046	)		280
	Financing Cash Flows			11,666			10,125			1,541
	Capital Expenditures(1)			(766	)		(1,046	)		280
	Cash, Cash Equivalents, and Restricted Cash	(2)		3,528			5,644			(2,116	)
	Merchandise Inventory (2)			37,353			30,248			7,105
(1)	Included in Investing Cash Flows
(2)	Cash and cash equivalents per condensed consolidated balance sheets		$	769		$	1,754		$	(985	)
	Add: restricted cash			2,759			3,890			(1,131	)
	Cash, cash equivalents, and restricted cash		$	3,528		$	5,644		$	(2,116	)

Cash used in operations was $12.2 million for the thirty-nine weeks ended October 29, 2022, primarily due to net loss of $12.4 million, an increase of $8.1 million in inventory, a decrease of $1.0 million in other long-term liabilities, net of a $6.4 million increase in accounts payable.

Cash used by investing activities was $0.8 million  and $1.1 million for the thirty-nine weeks periods ended October 29, 2022 and October 30, 2021, which consisted entirely of capital expenditures.

Cash provided by financing activities was $11.7 million for the thirty-nine weeks ended October 29, 2022.  The primary source of cash was $5.0 million raised from the issuance of subordinated debt and $7.1 million from the Private Placement offering partially offset by the payment of short-term borrowings of $0.5 million.

Cash provided by financing activities was $10.1 million for the thirty-nine weeks ended October 30, 2021.  The primary source of cash was an underwritten offering of 416,600 shares of common stock of the Company, at a price to the public of $32.50 per share. The net proceeds of the offering were approximately $12.2 million.  The Company used $6.3 million of the proceeds to pay down its Credit Facility.

Capital Expenditures.  During the thirteen weeks ended October 29, 2022, the Company made capital expenditures of $0.8 million. The Company currently plans to spend approximately $1.0 million for capital expenditures during fiscal 2022.

28

CRITICAL ACCOUNTING ESTIMATES

The preparation of financial statements and related disclosures in conformity with accounting principles generally accepted in the United States requires that management apply accounting policies and make estimates and assumptions that affect results of operations and the reported amounts of assets and liabilities in the financial statements.  Management continually evaluates its estimates and judgments including those related to merchandise inventory and return costs and income taxes.  Management bases its estimates and judgments on historical experience and other factors that are believed to be reasonable under the circumstances.  Actual results may differ from these estimates under different assumptions or conditions.

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations included in the Form 10-K as of and for the year ended January 29, 2022 includes a summary of the critical accounting policies and methods used by the Company in the preparation of its interim condensed consolidated financial statements.  The Company’s significant accounting policies are the same as those described in Note 1 to the Company’s Consolidated Financial Statements on Form 10-K for the fiscal year ended January 29, 2022.

Recent Accounting Pronouncements:

The information set forth under Note 2, Recently Adopted Accounting Pronouncements section contained in Item 1, “Notes to Interim Condensed Consolidated Financial Statements”, is incorporated herein by reference.

29

KASPIEN HOLDINGS INC. AND SUBSIDIARIES

PART I – FINANCIAL INFORMATION

Item 3 - Quantitative and Qualitative Disclosures about Market Risk

Not required under the requirements of a Smaller Reporting Company.

Item 4 – Controls and Procedures

(a)    Evaluation of disclosure controls and procedures.  The Company’s Principal  Executive Officer and Chief Financial Officer, after evaluating the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in the Securities Exchange Act of 1934 Rules 13a-15(e) and 15d-15(e)) as of October 29, 2022, have concluded that as of such date the Company’s disclosure controls and procedures were effective and designed to ensure that (i) information required to be disclosed by the issuer in the reports that it files or submits under the Securities Exchange Act of 1934 (the “Exchange Act”) is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and (ii) information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

(b)    Changes in internal controls.  There have been no changes in the Company’s internal controls over financial reporting that occurred during the fiscal quarter covered by this quarterly report that have materially affected, or are reasonably likely to materially affect, the Company’s internal controls over financial reporting.

30

KASPIEN HOLDINGS INC. AND SUBSIDIARIES

PART II - OTHER INFORMATION

Item 1 – Legal Proceedings

The Company is subject to legal proceedings and claims that have arisen in the ordinary course of its business and have not been finally adjudicated.  Although there can be no assurance as to the ultimate disposition of these matters, it is management’s opinion, based upon the information available at this time, that the expected outcome of these matters, individually and in the aggregate, will not have a material adverse effect on the results of operations and financial condition of the Company. As a result, the liability for the cases listed below is remote.

Retailer Agreement Dispute

On June 18, 2021, Vijuve Inc. filed a lawsuit against Kaspien Inc. in the United States District Court for the Eastern District of Washington (Case No. 2:21-cv-00192-SAB) concerning a Retailer Agreement that the parties entered into in September of 2020. Vijuve manufactures skin care products and face massagers. The parties agreed that Kaspien would sell Vijuve’s products on Amazon. The complaint alleged that Kaspien breached the Retailer Agreement when it declined to acquiesce to Vijuve’s demand that Kaspien purchase over $700,000 of products. In total, Vijuve is seeking $774,000 in damages. Kaspien denies that it breached the agreement. Moreover, on July 19, 2021, Kaspien filed counterclaims and alleged that Vijuve breached the contract, including by refusing to buy back inventory from Kaspien upon termination of the Retailer Agreement. Kaspien subsequently filed additional counterclaims against Vijuve for fraud and negligent misrepresentation. Kaspien is seeking at least $229,000 from Vijuve. A trial on all of the parties’ claims is scheduled for September 18, 2023. There is no determination of outcome, thus no contingencies are recognized as of the reporting date.

On February 17, 2022,  CA Washington, LLC (“CA”) filed a lawsuit against Kaspien, Inc. in Wake County, North Carolina Superior Court (court file 22 CVS 2051). CA claims that Kaspien, Inc. breached the contract between the parties by using CA’s technology platform to facilitate sales by third parties and by using CA’s technology to develop a competing platform. The lawsuit also includes an alternative claim for unjust enrichment and a claim for breach of North Carolina’s Unfair and Deceptive Trade Practices Act. CA seeks an unspecified amount of damages. Kaspien removed the lawsuit to federal court in the Eastern District of North Carolina (case number 5:22-cv-00111), filed an Answer denying CA’s claims, and asserted a counterclaim against CA for breach of contract and breach of the covenant of good faith and fair dealing. There is no determination of outcome, thus no contingencies are recognized as of the reporting date.

Item 1A – Risk Factors

Risks relating to the Company’s business and Common Stock are described in detail in Item 1A of the Company’s most recently filed Annual Report on Form 10-K for the fiscal year ended January 29, 2022.

Item 2 – Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3 – Defaults Upon Senior Securities

None.

Item 4 – Mine Safety Disclosure

Not Applicable.

31

Item 5 – Other Information

None.

Item 6 - Exhibits

(A) Exhibits -

Exhibit No.	Description
31.1	Chief Executive Officer certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Chief Financial Officer certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32	Certification pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS	XBRL Instance Document (furnished herewith)
101.SCH	XBRL Taxonomy Extension Schema (furnished herewith)
101.CAL	XBRL Taxonomy Extension Calculation Linkbase (furnished herewith)
101.DEF	XBRL Taxonomy Extension Definition Linkbase (furnished herewith)
101.LAB	XBRL Taxonomy Extension Label Linkbase (furnished herewith)
101.PRE	XBRL Taxonomy Extension Presentation Linkbase (furnished herewith)
104	Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).

32

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

KASPIEN HOLDINGS INC.
December 13, 2022	By: /s/ Brock Kowalchuk
	Brock Kowalchuk
	Principal Executive Officer
	(Principal Executive Officer)

December 13, 2022	By: /s/ Edwin Sapienza
	Edwin Sapienza
	Chief Financial Officer
	(Principal and Chief Accounting Officer)

33

EX-31.1

Exhibit 31.1

CHIEF EXECUTIVE OFFICER CERTIFICATION PURSUANT TO SECTION 302 OF SARBANES OXLEY ACT 2002

I, Brock Kowalchuk certify that:

(1) I have reviewed this report on Form 10–Q of the Registrant;

(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

(3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(4) The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

(5) The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated:   December 13, 2022	/s/ Brock Kowalchuk
	Brock Kowalchuk
	Principal Executive Officer
	Kaspien Holdings Inc.

EX-31.2

Exhibit 31.2

CHIEF FINANCIAL OFFICER CERTIFICATION PURSUANT TO SECTION 302 OF SARBANES OXLEY ACT 2002

I, Edwin Sapienza, Chief Financial Officer of Kaspien Holdings Inc. (the “Registrant”), certify that:

(1) I have reviewed this report on Form 10–Q of the Registrant;

(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

(3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(4) The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

(5) The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated:   December 13, 2022	/s/ Edwin Sapienza
	Edwin Sapienza
	Chief Financial Officer
	Kaspien Holdings Inc.

EX-32

Exhibit 32

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Kaspien Holdings Inc. (the “Company”) on Form 10-Q for the period ending October 29, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Brock Kowalchuk, Principal Executive Officer of the Company and Edwin Sapienza, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of our knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Brock Kowalchuk	/s/ Edwin Sapienza
Brock Kowalchuk	Edwin Sapienza
Principal Executive Officer	Chief Financial Officer
December 13, 2022	December 13, 2022

XML

Document and Entity Information - shares	9 Months Ended
	Oct. 29, 2022	Dec. 10, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Period End Date	Oct. 29, 2022
Current Fiscal Year End Date	--01-28
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Document Transition Report	false
Entity File Number	0-14818
Entity Registrant Name	KASPIEN HOLDINGS INC.
Entity Central Index Key	0000795212
Entity Incorporation, State or Country Code	NY
Entity Tax Identification Number	14-1541629
Entity Address, Address Line One	2818 N. Sullivan Rd.
Entity Address, Address Line Two	Ste 130
Entity Address, City or Town	Spokane Valley
Entity Address, State or Province	WA
Entity Address, Postal Zip Code	99216
City Area Code	855
Local Phone Number	300-2710
Title of 12(b) Security	Common Stock, $.01 par value per share
Trading Symbol	KSPN
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		4,964,753

XML

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Oct. 29, 2022	Jan. 29, 2022	Oct. 30, 2021
CURRENT ASSETS
Cash and cash equivalents	$ 769	$ 1,218	$ 1,754
Restricted cash	1,158	1,158	1,158
Accounts receivable	2,796	2,335	2,566
Merchandise inventory	37,353	29,277	30,248
Prepaid expenses and other current assets	706	649	760
Total current assets	42,782	34,637	36,486
Restricted cash	1,601	2,447	2,732
Fixed assets, net	2,140	2,335	2,251
Operating lease right-of-use assets	1,678	2,144	2,284
Cash Surrender Value	3,563	4,154	4,413
Other assets	682	965	1,074
TOTAL ASSETS	52,446	46,682	49,240
CURRENT LIABILITIES
Accounts payable	12,648	6,271	6,743
Short-term borrowings	9,494	9,966	5,858
Accrued expenses and other current liabilities	1,962	2,362	2,685
Current portion of operating lease liabilities	634	649	636
Total current liabilities	24,738	19,248	15,922
Operating lease liabilities	1,253	1,608	1,764
Long-term debt	9,163	4,356	4,161
Other long-term liabilities	13,590	14,185	15,515
TOTAL LIABILITIES	48,744	39,397	37,362
SHAREHOLDERS' EQUITY
Preferred stock ($0.01 par value; 5,000,000 shares authorized; none issued)	0	0	0
Common stock ($0.01 par value; 200,000,000 shares authorized; 5,321,985, 3,902,985 and 3,902,985 shares issued, respectively)	53	39	39
Additional paid-in capital	213,992	359,220	359,100
Treasury stock at cost (467,069, 1,410,378 and 1,410,378 shares, respectively)	(76,132)	(230,170)	(230,170)
Accumulated other comprehensive loss	(910)	(910)	(2,007)
Accumulated deficit	(133,301)	(120,894)	(115,084)
TOTAL SHAREHOLDERS' EQUITY	3,702	7,285	11,878
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$ 52,446	$ 46,682	$ 49,240

XML

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Oct. 29, 2022	Jan. 29, 2022	Oct. 30, 2021
SHAREHOLDERS' EQUITY
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	200,000,000	200,000,000	200,000,000
Common stock, shares issued (in shares)	5,321,985	3,902,985	3,902,985
Treasury stock (in shares)	467,069	1,410,378	1,410,378

XML

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 29, 2022	Oct. 30, 2021	Oct. 29, 2022	Oct. 30, 2021
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]
Net revenue	$ 29,145	$ 32,172	$ 94,843	$ 107,680
Cost of sales	22,570	24,168	74,688	81,044
Gross profit	6,575	8,004	20,155	26,636
Selling, general and administrative expenses	9,255	10,018	29,975	30,886
Loss from operations	(2,680)	(2,014)	(9,820)	(4,250)
Interest expense	881	439	2,544	1,455
Other income	0	(1,567)	0	(3,530)
Loss before income tax expense	(3,561)	(886)	(12,364)	(2,175)
Income tax expense	0	0	43	46
Net loss	$ (3,561)	$ (886)	$ (12,407)	$ (2,221)
BASIC AND DILUTED LOSS PER SHARE:
Basic loss per common share (in dollars per share)	$ (0.92)	$ (0.36)	$ (4.15)	$ (0.92)
Diluted loss per common share (in dollars per share)	$ (0.92)	$ (0.36)	$ (4.15)	$ (0.92)
Weighted average number of common shares outstanding - basic (in shares)	3,865	2,491	2,990	2,404
Weighted average number of common shares outstanding - diluted (in shares)	3,865	2,491	2,990	2,404

XML

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 29, 2022	Oct. 30, 2021	Oct. 29, 2022	Oct. 30, 2021
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS [Abstract]
Net loss	$ (3,561)	$ (886)	$ (12,407)	$ (2,221)
Amortization of pension gain	0	0	0	0
Comprehensive loss	$ (3,561)	$ (886)	$ (12,407)	$ (2,221)

XML

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($) shares in Thousands, $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock At Cost [Member]	Accumulated Other Comprehensive Loss [Member]	Retained Earnings (Accumulated Deficit) [Member]	Total
Balance at Jan. 30, 2021	$ 33	$ 346,495	$ (230,169)	$ (2,007)	$ (112,863)	$ 1,489
Balance (in shares) at Jan. 30, 2021	3,337		(1,410)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	$ 0	0	$ 0	0	(2,221)	(2,221)
Issuance of warrants	$ 2	0	$ (1)	0	0	1
Issuance of warrants (in shares)	138		0
Sale of shares, net of expense	$ 4	12,227	$ 0	0	0	12,231
Sale of shares, net of expense (in shares)	417		0
Exercise of stock options	$ 0	51	$ 0	0	0	51
Exercise of stock options (in shares)	2		0
Common stock issued- Director grants	$ 0	184	$ 0	0	0	184
Common stock issued- Director (in shares)	9		0
Amortization of unearned compensation/restricted stock amortization	$ 0	143	$ 0	0	0	143
Balance at Oct. 30, 2021	$ 39	359,100	$ (230,170)	(2,007)	(115,084)	11,878
Balance (in shares) at Oct. 30, 2021	3,903		(1,410)
Balance at Jul. 31, 2021	$ 39	359,016	$ (230,170)	(2,007)	(114,198)	12,680
Balance (in shares) at Jul. 31, 2021	3,903		(1,410)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	$ 0	0	$ 0	0	(886)	(886)
Amortization of unearned compensation/restricted stock amortization	0	84	0	0	0	84
Balance at Oct. 30, 2021	$ 39	359,100	$ (230,170)	(2,007)	(115,084)	11,878
Balance (in shares) at Oct. 30, 2021	3,903		(1,410)
Balance at Jan. 29, 2022	$ 39	359,220	$ (230,170)	(910)	(120,894)	7,285
Balance (in shares) at Jan. 29, 2022	3,903		(1,410)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	$ 0	0	$ 0	0	(12,407)	(12,407)
Issuance of shares, net of expenses	$ 0	(97,127)	$ 104,264	0	0	7,137
Issuance of shares, net of expenses (in shares)	0		638
Issuance of warrants	$ 0	1,518	$ 0	0	0	1,518
Issuance of warrants (in shares)	0		0
Exercise of warrants	$ 14	(49,788)	$ 49,774	0	0	0
Exercise of warrants (in shares)	1,403		305
Vested restricted shares	$ 0	1	$ 0	0	0	1
Vested restricted shares (in shares)	7		0
Common stock issued- Director grants	$ 0	41	$ 0	0	0	41
Common stock issued- Director (in shares)	9		0
Amortization of unearned compensation/restricted stock amortization	$ 0	128	$ 0	0	0	128
Balance at Oct. 29, 2022	$ 53	213,992	$ (76,132)	(910)	(133,301)	3,702
Balance (in shares) at Oct. 29, 2022	5,322		(467)
Balance at Jul. 30, 2022	$ 39	263,723	$ (125,906)	(910)	(129,740)	7,206
Balance (in shares) at Jul. 30, 2022	3,912		(772)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	$ 0	0	$ 0	0	(3,561)	(3,561)
Issuance of shares, net of expenses	$ 0	0	$ 0	0	0	0
Issuance of shares, net of expenses (in shares)	0		0
Exercise of warrants	$ 14	(49,788)	$ 49,774	0	0	0
Exercise of warrants (in shares)	1,403		305
Common stock issued-Restricted share units	$ 0	1	$ 0	0	0	1
Common stock issued-Restricted share units (in shares)	7		0
Amortization of unearned compensation/restricted stock amortization	$ 0	57	$ 0	0	0	57
Balance at Oct. 29, 2022	$ 53	$ 213,992	$ (76,132)	$ (910)	$ (133,301)	$ 3,702
Balance (in shares) at Oct. 29, 2022	5,322		(467)

XML

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Oct. 29, 2022	Oct. 30, 2021
OPERATING ACTIVITIES:
Net loss	$ (12,407)	$ (2,221)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of fixed assets	961	1,064
Amortization of intangible assets	0	732
Stock-based compensation	169	327
Amortization of ROU asset	466	458
Amortization of warrant interest	766	191
Interest on long term debt	849	570
Change in cash surrender value	591	(557)
Forgiveness of PPP Loan	0	(1,963)
Changes in operating assets and liabilities that provide (use) cash:
Accounts receivable	(461)	150
Merchandise inventory	(8,075)	(5,732)
Prepaid expenses and other current assets	(56)	(196)
Other long-term assets	283	268
Accounts payable	6,377	(2,150)
Accrued expenses and other current liabilities	(706)	236
Other long-term liabilities	(951)	(1,167)
Net cash used in operating activities	(12,194)	(9,990)
INVESTING ACTIVITIES:
Purchases of fixed assets	(766)	(1,046)
Net cash provided by (used in) investing activities	(766)	(1,046)
FINANCING ACTIVITIES:
Proceeds from long term borrowings	5,000	0
Proceeds from issuance of shares, net of expense	7,137	12,231
Proceeds from exercise of stock options	0	51
Payments of PPP loan	0	(76)
Payment of short term borrowings	(9,966)	(6,339)
Payments of long term borrowings	0	(1,600)
Proceeds from short term borrowings	9,494	5,858
Net cash provided by (used in) financing activities	11,665	10,125
Net increase (decrease) in cash, cash equivalents, and restricted cash	(1,295)	(911)
Cash, cash equivalents, and restricted cash, beginning of period	4,823	6,555
Cash, cash equivalents, and restricted cash, end of period	3,528	5,644
Supplemental disclosures and non-cash investing and financing activities:
Interest paid	461	295
Warrants issued with debt	$ 1,633	$ 0

XML

Nature of Operations

9 Months Ended

Oct. 29, 2022

Nature of Operations [Abstract]

Nature of Operations

Note 1. Nature of Operations

Kaspien Holdings Inc., which, together with its consolidated subsidiaries, is referred to herein as “Kaspien”, “the Company”, “we”, “us” and “our”, was incorporated in New York in 1972. We own 100% of the outstanding common stock of Kaspien Inc, through which our principal operations are conducted. Kaspien provides a platform of software and services to empower brands to grow their online distribution channels on digital marketplaces such as Amazon, Walmart, Target, eBay, among others. The Company helps brands achieve their online retail goals through its innovative and proprietary technology, tailored strategies, and mutually beneficial partnerships.

Kaspien provides a platform of software and services to empower brands to grow their online distribution channels on digital marketplaces such as Amazon, Walmart and Target, among others. The Company helps brands achieve their online retail goals through its innovative and proprietary technology, tailored strategies and mutually beneficial partnerships.

We are guided by 5 core principles:

• We are partner obsessed. Our customers are our partners. Every decision is focused on building mutually beneficial relationships that deliver results.

• We are insights driven. We make data actionable. Our curiosity drives us to discover opportunities early and often.

• We create simplicity. We challenge the status quo. We take the complicated and simplify it.

• We take ownership. We make things happen. We hold ourselves accountable and have a bias for action.

• We empower each other. We welcome and learn from diverse experiences. Our empathy ignites innovation and empowers meaningful change.

Liquidity and Cash Flows:

The Company’s primary sources of liquidity are its borrowing capacity under its Credit Facility, available cash and cash equivalents, and to a lesser extent, cash generated from operations. Our cash requirements relate primarily to working capital needed to operate Kaspien, including funding operating expenses, the purchase of inventory and capital expenditures.

The Company incurred a net loss of $12.4 million and $2.2 million for the thirty-nine weeks ended October 29, 2022 and October 30, 2021, respectively.  The increase in the net loss was primarily attributable to a decrease in sales and gross margin. In addition, the Company has an accumulated deficit of $133.3 million as of October 29, 2022 and net cash used in operating activities for the thirty-nine weeks ended October 29, 2022 was $12.2 million. Net cash used in operating activities for the thirty-nine weeks ended October 30, 2021 was $10.0 million.

As disclosed in the Company’s Annual Report on Form 10-K filed April 29, 2022, the Company experienced negative cash flows from operations during fiscal 2021 and 2020 and we expect to incur net losses in fiscal 2022.

Our ability to achieve profitability and meet future liquidity needs and capital requirements will depend upon numerous factors, including the timing and amount of our revenue; the timing and amount of our operating expenses; the timing and costs of working capital needs; successful implementation of our strategy and planned activities; and our ability to overcome the impact of the COVID-19 pandemic. There can be no assurance that we will be successful in further implementing our business strategy or that the strategy, including the completed initiatives, will be successful in sustaining acceptable levels of sales growth and profitability. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.

The unaudited condensed consolidated financial statements for the thirteen and thirty-nine weeks ended October 29, 2022 were prepared pursuant to the rules and regulations of the Securities and Exchange Commission. The information furnished in these unaudited condensed consolidated financial statements reflects all normal, recurring adjustments which, in the opinion of management, are necessary for the fair presentation of such financial statements. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The ability of the Company to meet its liabilities and to continue as a going concern is dependent on improved profitability, the strategic initiatives for Kaspien and the availability of future funding. Based on recurring losses from operations, negative cash flows from operations, the expectation of continuing operating losses for the foreseeable future, and uncertainty with respect to any available future funding, the Company has concluded that there is substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

As of October 29, 2022, we had cash and cash equivalents of $0.8 million, net working capital of $18.0 million, and $9.5 in borrowings on our revolving credit facility, as further discussed below.

As of January 29, 2022, the Company had borrowings of $10.0 million under the Credit Facility. As of October 29, 2022 and October 30, 2021, the Company had no outstanding letters of credit. The Company had $5.2 million and $10.9 million available for borrowing under the Credit Facility as of October 29, 2022 and October 30, 2021, respectively.

On March 18, 2021, the Company closed an underwritten offering of 416,600 shares of common stock of the Company, at a price to the public of $32.50 per share. The gross proceeds of the offering were approximately $13.5 million, prior to deducting underwriting discounts and commissions and estimated offering expenses. The Company used the net proceeds from the offering for general corporate purposes, including working capital to implement its strategic plans, investments in technology to enhance its scalable platform and its core retail business.

Credit Facility

On February 20, 2020, Kaspien Inc. entered into a Loan and Security Agreement (as subsequently amended, the “Loan Agreement”) with Eclipse Business Capital LLC (f/k/a Encina Business Credit, LLC) (“Eclipse”), as administrative agent, under which the lenders party thereto committed to provide up to $25 million in loans under a four-year, secured revolving credit facility (the “Credit Facility”).

On March 30, 2020, the Company and Kaspien Inc. (the “Loan Parties”) entered into Amendment No. 1 to the Loan Agreement (the “Amendment”). Pursuant to the Amendment, among other things, (i) the Company was added as “Parent” under the Amended Loan Agreement, (ii) the Company granted a first priority security interest in substantially all of the assets of the Company, including inventory, accounts receivable, cash and cash equivalents and certain other collateral, and (iii) the Loan Agreement was amended to (a) permit the incurrence of certain subordinated indebtedness under the Subordinated Loan Agreement (as defined below) and (b) limit the Company’s ability to incur additional indebtedness, create liens, make investments, make restricted payments or specified payments and merge or acquire assets.

On April 7, 2021, the Loan Parties entered into Amendment No. 2 to the Loan Agreement (the “Second Amendment”. Pursuant to the Second Amendment, the In-Transit Inventory Sublimit (as defined in the Loan Agreement) was increased from $2,000,000 to $2,500,000.

On September 17, 2021, the Loan Parties entered into Amendment No. 3 to the Loan Agreement (the “Third Amendment”). Pursuant to the Third Amendment, among other things, (i) the maturity of the Credit Facility has been extended to February 20, 2024, and the early termination fees have been accordingly reset; (ii) the LIBOR floor has been reduced to 1.00%; (iii) up to $4,000,000 of acquisitions are now allowed without Eclipse’s consent, subject to satisfaction of various conditions, including the Company having a trailing twelve month fixed charge coverage ratio of 1.20x and Excess Availability greater than the greater of (x) 20% of the average Borrowing Base for each 30 day period immediately prior to, and pro forma for, the purchase and (y) $1,500,000.

On March 2, 2022, the Loan Parties entered into Amendment No. 4 to the Loan Agreement (the “Fourth Amendment”). Pursuant to the Fourth Amendment, among other things, the Credit Facility was amended to permit the incurrence of the Additional Subordinated Loan (as defined below) under the Subordinated Loan Agreement (as defined below).

On November 1, 2022, the Loan Parties entered into Amendment No. 5 to the loan agreement (the “Fifth Amendment”). Pursuant to the Fifth Amendment, the Credit Facility was amended to replace LIBOR with the Secured Overnight Funding Rate (“SOFR”).

As of October 29, 2022 and October 30, 2021, the Company had borrowings of $9.5 and $5.9 million under the Credit Facility, respectively.

Subordinated Debt Agreement

On March 30, 2020, the Loan Parties entered into a Subordinated Loan and Security Agreement (the “Subordinated Loan Agreement”) with the lenders party thereto from time to time (the “Lenders”) and TWEC Loan Collateral Agent, LLC (the “Collateral Agent”), as collateral agent for the Lenders, pursuant to which the Lenders made a $5.2 million secured term loan (the “Subordinated Loan”) to Kaspien with a scheduled maturity date of May 22, 2023. As of October 29, 2022, unamortized debt issuance costs of $0.1 million are included in “Long Term Debt” on the unaudited condensed consolidated balance sheet.

Directors Jonathan Marcus, Thomas Simpson, and Michael Reickert are the chief executive officer of Alimco Re Ltd. (“Alimco”), the managing member of Kick-Start III, LLC and Kick-Start IV, LLC (“Kick-Start”), and a trustee of the Robert J. Higgins TWMC Trust (the “Trust”), an affiliate of RJHDC, LLC (“RJHDC” and together with Alimco and Kick-Start, “Related Party Entities”), respectively.  The Related Party Entities are parties to the Subordinated Loan Agreement.

Amendment No. 2 to Subordinated Loan and Security Agreement

On March 2, 2022, the Loan Parties entered into that certain Amendment No. 2 to Subordinated Loan and Security Agreement (“Amendment No. 2”) with the “Lenders and the Collateral Agent. Pursuant to Amendment No. 2, among other things, Alimco Re Ltd. (the “Tranche B Lender”) made an additional $5,000,000 secured term loan (the “Additional Subordinated Loan”) with a scheduled maturity date of March 31, 2024, which is the same maturity date as the existing loans under the Subordinated Loan Agreement.

Interest on the Additional Subordinated Loan accrues, subject to certain terms and conditions under the Subordinated Loan Agreement, at the rate of fifteen percent (15.0%) per annum, compounded on the last day of each calendar quarter by becoming a part of the principal amount of the Additional Subordinated Loan.

The Additional Subordinated Loan is also secured by a second priority security interest in substantially all of the assets of the Loan Parties, including inventory, accounts receivable, cash and cash equivalents and certain other collateral of the borrowers and guarantors under the Subordinated Loan Agreement. The Company will provide a limited guarantee of Kaspien’s obligations under the Additional Subordinated Loan.

Among other things, the Subordinated Loan Agreement limits the Loan Parties’ ability to incur additional indebtedness, create liens, make investments, make restricted payments or specified payments and merge or acquire assets.

The Subordinated Loan Agreement contains customary events of default, including, but not limited to, payment defaults, breaches of representations and warranties, covenant defaults, cross-defaults to other obligations, customary ERISA defaults, certain events of bankruptcy and insolvency, judgment defaults, the invalidity of liens on collateral, change in control, cessation of business or the liquidation of material assets of the borrowers and guarantors thereunder taken as a whole and the occurrence of an uninsured loss to a material portion of collateral.

The Loan Parties paid certain customary fees and expenses in connection with the Additional Subordinated Loan and Amendment No. 2.

Paycheck Protection Program

On April 17, 2020, Kaspien received loan proceeds of $2.0 million (the “PPP Loan”) pursuant to the Paycheck Protection Program (“PPP”) under the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”). On June 14, 2021, the Small Business Administration (“SBA”) approved the Company’s application for forgiveness of the PPP Loan. The amount of the forgiveness was $1.9 million in principal and interest, which was the amount requested in the forgiveness application and was less than the original principal balance due of $2.0 million. Following the grant of forgiveness, an outstanding balance of $76,452 was paid during fiscal 2021.

In addition to the aforementioned current sources of existing working capital, the Company may explore certain other strategic alternatives that may become available to the Company, as well continuing our efforts to generate additional sales and increase margins. However, at this time the Company has no commitments to obtain any additional funds, and there can be no assurance such funds will be available on acceptable terms or at all, should we require such additional funds. If the Company is unable to improve its operations, it may be required to obtain additional funding, and the Company’s financial condition and results of operations may be materially adversely affected.

Furthermore, broad market and industry factors may seriously harm the market price of our common stock, regardless of our operating performance, and may adversely impact our ability to raise additional funds, should we require such additional funds.

Impact of COVID-19

The full extent to which the COVID-19 pandemic will continue to directly or indirectly impact our business, results of operations and financial condition, including expenses, reserves and allowances, and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19, including the actions taken to contain or treat it, as well as the economic impact on local, regional, national and international customers and markets, which are highly uncertain and cannot be predicted at this time. Our leadership team believes we have the necessary controls in place to mitigate these impacts.

XML

Basis of Presentation

9 Months Ended

Oct. 29, 2022

Basis of Presentation [Abstract]

Basis of Presentation

Note 2. Basis of Presentation

The accompanying interim condensed consolidated financial statements consist of Kaspien Holdings Inc., its wholly owned subsidiaries, Kaspien NY, LLC (f/k/a Trans World NY Sub, Inc. (f/k/a Record Town, Inc.)) and its subsidiaries, and Kaspien, Inc. All intercompany accounts and transactions have been eliminated.

The interim condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. The information furnished in these unaudited interim condensed consolidated financial statements reflects all normal, recurring adjustments which, in the opinion of management, are necessary for the fair presentation of such financial statements. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of net revenue and expenses during the reporting period. Actual results could differ from those estimates. Certain information and footnote disclosures normally included in the financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to rules and regulations applicable to interim financial statements.

The accompanying unaudited interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto and Management’s Discussion and Analysis of Financial Condition and Results of Operations as of and for the year ended January 29, 2022 contained in the Company’s Annual Report on Form 10-K filed April 29, 2022.  The results of operations for the thirteen and thirty-nine weeks ended October 29, 2022 are not necessarily indicative of the results to be expected for the entire fiscal year ending January 28, 2023.

The Company’s significant accounting policies are the same as those described in Note 1 to the Company’s Consolidated Financial Statements on Form 10-K for the fiscal year ended January 29, 2022.

XML

Recently Adopted Accounting Pronouncements

9 Months Ended

Oct. 29, 2022

Recently Adopted Accounting Pronouncements [Abstract]

Recently Adopted Accounting Pronouncements

Note 3. Recently Adopted Accounting Pronouncements

In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,” which introduced an expected credit loss model for the impairment of financial assets measured at amortized cost. The model replaces the probable, incurred loss model for those assets and instead, broadens the information an entity must consider in developing its expected credit loss estimate for assets measured at amortized cost. This standard will be effective for smaller reporting companies for fiscal years beginning after December 15, 2022, however early adoption is permitted. We are currently evaluating the impact of this new standard on the consolidated financial statements.

In March 2020, the FASB issued ASU No. 2020-04, “Reference Rate Reform (Topic 848): facilitation of the Effects of Reference Rate Reform on Financial Reporting” (“ASU 2020-04”). ASU 2020-04 provides optional expedients and exceptions for applying U.S. GAAP to contract modifications and hedging relationships that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. ASU 2020-04 provides, among other things, guidance that modifications of contracts within the scope of Topic 470, Debt, should be accounted for by prospectively adjusting the effective interest rate; modifications of contracts within the scope of Topic 840, Leases, should be accounted for as a continuation of the existing contract; and, changes in the critical terms of hedging relationships, caused by reference rate reform, should not result in the de-designation of the instrument, provided certain criteria are met. The Company’s exposure to LIBOR rates includes its credit facility. The amendments are effective as of March 12, 2020 through December 31, 2022. Adoption is permitted at any time. The Company is currently evaluating the impact this update will have on its Condensed Consolidated Financial Statements.

Recent accounting pronouncements pending adoption not discussed above are either not applicable or are not expected to have a material impact on our consolidated financial condition, results of operations, or cash flows.

XML

Intangible Assets

9 Months Ended

Oct. 29, 2022

Intangible Assets [Abstract]

Intangible Assets

Note 4. Intangible Assets

The determination of the fair value of intangible assets acquired in a business acquisition, including the Company’s acquisition of Kaspien in 2016, is subject to many estimates and assumptions. Our identifiable intangible assets that resulted from our acquisition of Kaspien consist of  technology and tradenames. As of October 30, 2021, the intangible assets were fully amortized. Amortization expense of intangible assets for the thirteen and thirty-nine weeks ended October 29, 2022 and October 30, 2021 consisted of the following:

	Thirteen Weeks Ended				Thirty-nine Weeks Ended
	October 29,		October 30,		October 29,		October 30,
(amounts in thousands)	2022		2021		2022		2021
Amortized intangible assets:
Technology	$	-	$	65	$	-	$	259
Trade names and trademarks		-		153		-		473
Total amortization expense	$	-	$	218	$	-	$	732

XML

Depreciation and Amortization

9 Months Ended

Oct. 29, 2022

Depreciation and Amortization [Abstract]

Depreciation and Amortization

Note 5. Depreciation and Amortization

Depreciation and amortization included in selling, general and administrative expenses of the interim condensed consolidated statements of operations for the thirteen weeks ended October 29, 2022 and October 30, 2021 was $0.4 million and $0.6 million, respectively.

Depreciation and amortization included in selling, general and administrative expenses of the interim condensed consolidated statements of operations for the thirty-nine weeks ended October 29, 2022 and October 30, 2021 was $1.0 million and $1.8 million, respectively.

XML

Restricted Cash

9 Months Ended

Oct. 29, 2022

Restricted Cash [Abstract]

Restricted Cash

Note 6. Restricted Cash

As a result of the death of its former Chairman, the Company holds $2.8 million in a rabbi trust, of which $1.2 million is classified as restricted cash in current assets and $1.6 million is classified as restricted cash in other assets on the accompanying interim condensed consolidated balance sheet as of October 29, 2022.

A summary of cash, cash equivalents and restricted cash is as follows (amounts in thousands):

	October 29,		January 29,		October 30,
	2022		2022		2021
Cash and cash equivalents	$	769	$	1,218	$	1,754
Restricted cash		2,759		3,605		3,890
Total cash, cash equivalents and restricted cash	$	3,528	$	4,823	$	5,644

XML

Debt

9 Months Ended

Oct. 29, 2022

Debt [Abstract]

Debt

Note 7.  Debt

Credit Facility

On February 20, 2020, Kaspien Inc. entered into a Loan and Security Agreement (as subsequently amended, the “Loan Agreement”) with Eclipse Business Capital LLC (f/k/a Encina Business Credit, LLC) (“Eclipse”), as administrative agent, under which the lenders party thereto committed to provide up to $25 million in loans under a four-year, secured revolving credit facility (the “Credit Facility”).

The commitments by the lenders under the Credit Facility are subject to borrowing base and availability restrictions. Up to $5.0 million of the Credit Facility may be used for the making of swing line loans.

Interest under the Credit Facility accrues, subject to certain terms and conditions under the Loan Agreement, at a LIBOR Rate or Base Rate, plus, in each case, an Applicable Margin, which is determined by reference to the level of Availability as defined in the Loan Agreement, with the Applicable Margin for LIBOR Rate loans ranging from 4.00% to 4.50% and the Applicable Margin for Base Rate loans ranging from 3.00% to 3.50%.

The Credit Facility is secured by a first priority security interest in substantially all of the assets of Kaspien, including inventory, accounts receivable, cash and cash equivalents and certain other collateral of the borrowers and guarantors under the Credit Facility (collectively, the “Credit Facility Parties”) and by a first priority pledge by the Company of its equity interests in Kaspien. The Company will provide a limited guarantee of Kaspien’s obligations under the Credit Facility.

Among other things, the Loan Agreement limits Kaspien’s ability to incur additional indebtedness, create liens, make investments, make restricted payments or specified payments and merge or acquire assets. The Loan Agreement also requires Kaspien to comply with a financial maintenance covenant.

The Loan Agreement contains customary events of default, including, but not limited to, payment defaults, breaches of representations and warranties, covenant defaults, cross-defaults to other obligations, customary ERISA defaults, certain events of bankruptcy and insolvency, judgment defaults, the invalidity of liens on collateral, change in control, cessation of business or the liquidation of material assets of the Credit Facility Parties taken as a whole, the occurrence of an uninsured loss to a material portion of collateral and failure of the obligations under the Credit Facility to constitute senior indebtedness under any applicable subordination or intercreditor agreements.

On March 30, 2020, the Company and Kaspien (the “Loan Parties”) entered into Amendment No. 1 to the Loan Agreement (the “Amendment”). Pursuant to the Amendment, among other things, (i) the Company was added as “Parent” under the Amended Loan Agreement, (ii) the Company granted a first priority security interest in substantially all of the assets of the Company, including inventory, accounts receivable, cash and cash equivalents and certain other collateral, and (iii) the Loan Agreement was amended to (a) permit the incurrence of certain subordinated indebtedness under the Subordinated Loan

Agreement (as defined below) and (b) limit the Company’s ability to incur additional indebtedness, create liens, make investments, make restricted payments or specified payments and merge or acquire assets.

On April 7, 2021, Loan Parties entered into Amendment No. 2 to the Loan Agreement (the “Second Amendment”. Pursuant to the Second Amendment, the In-Transit Inventory Sublimit (as defined in the Loan Agreement) was increased from $2,000,000 to $2,500,000.

On September 17, 2021, the Loan Parties entered into Amendment No. 3 to the Loan Agreement (the “Third Amendment”). Pursuant to the Third Amendment, among other things, (i) the maturity of the credit facility has been extended to February 20, 2024, and the early termination fees have been accordingly reset; (ii) the LIBOR floor has been reduced to 1.00%; (iii) up to $4,000,000 of acquisitions are now allowed without Eclipse’s consent, subject to satisfaction of various conditions, including the Company having a trailing twelve month fixed charge coverage ratio of 1.20x and Excess Availability greater than the greater of (x) 20% of the average Borrowing Base for each 30 day period immediately prior to, and pro forma for, the purchase and (y) $1,500,000.

On March 2, 2022, the Loan Parties entered into Amendment No. 4 to the Loan Agreement (“Fourth Amendment”). Pursuant to the Fourth Amendment, among other things, the Credit Facility was amended to permit the incurrence of the Additional Subordinated Loan (as defined below) under the Subordinated Loan Agreement (as defined below).

On November 1, 2022, the Loan Parties entered into Amendment No. 5 to the Loan Agreement (the “Fifth Amendment”). Pursuant to the Fifth Amendment, the Credit Facility was amended to replace LIBOR with the Secured Overnight Funding Rate (“SOFR”).

As of October 29, 2022, the Company had borrowings of $9.5 million under the Credit Facility. The Company had borrowings of $5.9 million as of October 30, 2021. As of October 29, 2022, unamortized debt issuance costs of $0.1 million related to the Credit Facility are included in Other assets on the unaudited condensed consolidated balance sheet.

The Company records short term borrowings at cost, in which the carrying value approximates fair value due to its short-term maturity.

Subordinated Loan Agreement

On March 30, 2020, the Loan Parties entered into a Subordinated Loan and Security Agreement (the “Subordinated Loan Agreement”) with the lenders party thereto from time to time (the “Lenders”) and TWEC Loan Collateral Agent, LLC (the “Collateral Agent”), as collateral agent for the Lenders, pursuant to which the Lenders made a $5.2 million secured term loan (the “Subordinated Loan”) to Kaspien. On September 17, 2021, the Loan Parties entered into Amendment No. 1 to the Subordinated Loan Agreement which extended the maturity of the loan to March 31, 2024. As of October 29, 2022, unamortized debt issuance costs of $0.1 million are included in “Long-Term Debt” on the consolidated balance sheet.

Interest on the Subordinated Loan accrues, subject to certain terms and conditions under the Subordinated Loan Agreement, at the rate of twelve percent (12.0%) per annum, compounded on the last day of each calendar quarter by becoming a part of the principal amount of the Subordinated Loan.

The Subordinated Loan is secured by a second priority security interest in substantially all of the assets of the Loan Parties, including inventory, accounts receivable, cash and cash equivalents and certain other collateral of the borrowers and guarantors under the Subordinated Loan Agreement (collectively, the “Second Lien Credit Facility Parties”). The Company will provide a limited guarantee of Kaspien ’s obligations under the Subordinated Loan.

Among other things, the Subordinated Loan Agreement limits the Loan Parties’ ability to incur additional indebtedness, create liens, make investments, make restricted payments or specified payments and merge or acquire assets.

The Subordinated Loan Agreement contains customary events of default, including, but not limited to, payment defaults, breaches of representations and warranties, covenant defaults, cross-defaults to other obligations, customary ERISA defaults, certain events of bankruptcy and insolvency, judgment defaults, the invalidity of liens on collateral, change in control, cessation of business or the liquidation of material assets of the Second Lien Credit Facility Parties taken as a whole and the occurrence of an uninsured loss to a material portion of collateral.

In conjunction with the Subordinated Debt Agreement, the Company issued warrants to purchase up to 244,532 shares of Common Stock to the Related Party Entities (127,208 shares for Alimco, 23,401 shares for Kick-Start, and 93,923 shares for RJHDC), subject to adjustment in accordance with the terms of the Warrants, at an exercise price of $0.01 per share. As of October 29, 2022, 7,539 warrants remain outstanding.

The value of the warrants of $0.7 million was allocated against the principal proceeds of the Subordinated Debt Agreement, $0.2 million of which was unamortized as of October 29, 2022.

On March 2, 2022, the Loan Parties entered into that certain Amendment No. 2 to Subordinated Loan and Security Agreement (“Amendment No. 2”) the “Lenders and Collateral Agent. Pursuant to Amendment No. 2, among other things, Alimco Re Ltd. (the “Tranche B Lender”) made an additional $5,000,000 secured term loan (the “Additional Subordinated Loan”) with a scheduled maturity date of March 31, 2024, which is the same maturity date as the existing loans under the Subordinated Loan Agreement.

Interest on the Additional Subordinated Loan accrues, subject to certain terms and conditions under the Subordinated Loan Agreement, at the rate of fifteen percent (15.0%) per annum, compounded on the last day of each calendar quarter by becoming a part of the principal amount of the Additional Subordinated Loan.

The Additional Subordinated Loan is also secured by a second priority security interest in substantially all of the assets of the Loan Parties, including inventory, accounts receivable, cash and cash equivalents and certain other collateral of the borrowers and guarantors under the Subordinated Loan Agreement. The Company will provide a limited guarantee of Kaspien’s obligations under the Additional Subordinated Loan.

Among other things, the Subordinated Loan Agreement limits the Loan Parties’ ability to incur additional indebtedness, create liens, make investments, make restricted payments or specified payments and merge or acquire assets.

The Subordinated Loan Agreement contains customary events of default, including, but not limited to, payment defaults, breaches of representations and warranties, covenant defaults, cross-defaults to other obligations, customary ERISA defaults, certain events of bankruptcy and insolvency, judgment defaults, the invalidity of liens on collateral, change in control, cessation of business or the liquidation of material assets of the borrowers and guarantors thereunder taken as a whole and the occurrence of an uninsured loss to a material portion of collateral.

In conjunction with the Subordinated Debt Agreement, the Company issued warrants to purchase up to warrants to purchase up to 320,000 shares of common stock of the Company (subject to adjustment in accordance with the terms of the Warrants, the “Warrant Shares”) at an exercise price of $0.01 per share.  The Warrants are exercisable during the period commencing on March 2, 2022 and ending on the earlier of (a) 5:00 p.m. Eastern Standard Time on the five (5)-year anniversary thereof, or if such day is not a business day on the next succeeding business day, or (b) the occurrence of certain consolidations, mergers or similar extraordinary events involving the Company. As of October 29, 2022, all of the warrants remain outstanding.

The value of the warrants of $1.6 million was allocated against the principal proceeds of the Subordinated Debt Agreement, of which $1.1 million was unamortized as of October 29, 2022. The value of the warrants was recognized as a discount based on the relative fair value of the consideration received, as an offset to APIC, which will be amortized over the life of the loan.

Paycheck Protection Program

On April 17, 2020, Kaspien received loan proceeds of $2.0 million (the “PPP Loan”) pursuant to the Paycheck Protection Program (“PPP”) under the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”). On June 14, 2021, the Small Business Administration (“SBA”) approved the Company’s application for forgiveness of the PPP Loan. The amount of the forgiveness was $1.9 million in principal and interest, which was the amount requested in the forgiveness application and was less than the original principal balance due of $2.0 million. Following the grant of forgiveness, an outstanding balance of $76,452 was paid during fiscal 2021.

XML

Stock Based Compensation

9 Months Ended

Oct. 29, 2022

Stock Based Compensation [Abstract]

Stock Based Compensation

Note 8. Stock Based Compensation

The Company has outstanding awards under three employee stock award plans, the 2005 Long Term Incentive and Share Award Plan, the Amended and Restated 2005 Long Term Incentive and Share Award Plan (the “Old Plans”); and 2005 Long Term Incentive and Share Award Plan, as amended and restated on August 2, 2022 (the “New Plan”). Collectively, these plans are referred to herein as the Stock Award Plans. The Company no longer issues stock options under the Old Plans.

Equity awards authorized for issuance under the New Plan total 500,000. As of October 29, 2022, of the awards authorized for issuance under the Stock Award Plans, 70,364 options were granted and are outstanding, 25,294 of which were vested and exercisable. Shares available for future grants of options and other share-based awards under the New Plan as of October 29, 2022 were 497,000.

The following table summarizes stock award activity during the thirteen weeks ended October 29, 2022:

	Employee Stock Award Plans
	Number of Shares Subject To Option			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term		Other Share Awards (1)			Weighted Average Grant Fair Value
Balance January 29, 2022		85,965		$	13.41		7.5		90,000		$	15.39
Granted		21,750			5.57		9.9		9,000			4.59
Forfeited		(20,045	)		9.31		9.1		(63,500	)		14.08
Canceled		(17,306	)		15.56		-		-			-
Exercised		-			-		-		(12,000	)		10.77
Balance October 29, 2022		70,364		$	10.23		7.6		23,500		$	17.69
Exercisable October 29, 2022		25,294		$	18.70		6.2		-		$	-

 ⁽¹⁾ Other Share Awards include restricted share units granted to employees and directors.

As of October 29, 2022, the intrinsic value of stock awards outstanding and stock awards exercisable was $0.

XML

Shareholders' Equity

9 Months Ended

Oct. 29, 2022

Shareholders' Equity [Abstract]

Shareholders' Equity

Note 9. Shareholders’ Equity

On July 12, 2022, the Company entered into a Securities Purchase Agreement (the “PIPE Purchase Agreement”) with a single institutional investor for a private placement offering (“Private Placement”) of the Company’s common stock (the “Common Stock”) or pre-funded warrants, with each pre-funded warrant exercisable for one share of Common Stock (the “Pre-Funded Warrants”), and warrants exercisable for one share of Common Stock (the “Investor Warrants”). Pursuant to the PIPE Purchase Agreement, the Company has agreed to issue and sell 1,818,182 shares (the “Shares”) of its Common Stock or Pre-Funded Warrants in lieu thereof together with Investor Warrants to purchase up to 2,457,160 shares of Common Stock. Each share of Common Stock and accompanying Investor Warrant will be sold together at a combined offering price of $3.30 per share.

The Pre-Funded Warrants are immediately exercisable, at a nominal exercise price of $0.001, and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full.

The Investor Warrants have an exercise price of $3.13 per share (subject to adjustment as set forth in the warrant), are exercisable upon issuance and will expire five years from the date of issuance. The Investor Warrants contain standard adjustments to the exercise price including for stock splits, stock dividend, rights offerings and pro rata distributions.

The Private Placement closed on July 14, 2022. The Company received approximately $6 million in gross proceeds from the Private Placement, before deducting discounts and commissions and estimated offering expenses. The Company intends to use the net proceeds from the private placement for working capital and other general corporate purposes.

On July 12, 2022, the Company also entered into a Securities Purchase Agreement (the “Registered Purchase Agreement”) with a single institutional investor, pursuant to which the Company agreed to issue and sell 638,978 shares (the “Registered Shares”) of its Common Stock or Pre-Funded Warrants in lieu thereof, with each Pre-Funded Warrant exercisable for one share of Common Stock (the “Offering”). The Company received approximately $2 million in gross proceeds from the Offering, before deducting discounts and commissions and estimated offering expenses. The Company intends to use the net proceeds from the private placement for working capital and other general corporate purposes.

The Pre-Funded Warrants are immediately exercisable, at a nominal exercise price of $0.001, and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. As of October 29, 2022 109,416 Pre-Funded Warrants related to the Offering remain outstanding.

Net proceeds from the Private Placement and the Offering, after deducting placement agent fees and other estimated offering expenses payable by the Company of $0.9 million, were approximately $7.1 million.

The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company, all of which were exercisable, as of October 29, 2022:

Exercise		Number
Price		Outstanding
$	0.001		109,416
$	0.01		327,539
$	0.125		2,457,160
			2,894,115

XML

Accumulated Other Comprehensive Loss

9 Months Ended

Oct. 29, 2022

Accumulated Other Comprehensive Loss [Abstract]

Accumulated Other Comprehensive Loss

Note 10. Accumulated Other Comprehensive Loss

Accumulated other comprehensive loss that the Company reports in the interim condensed consolidated balance sheets represents net loss, adjusted for the difference between the accrued pension liability and accrued benefit cost, net of taxes, associated with the Company’s defined benefit plan. Comprehensive loss consists of net loss for all periods presented.

XML

Defined Benefit Plan

9 Months Ended

Oct. 29, 2022

Defined Benefit Plan [Abstract]

Defined Benefit Plan

Note 11. Defined Benefit Plan

The Company maintains a non-qualified Supplemental Executive Retirement Plan (“SERP”) for certain executive officers of the Company.  The SERP provides eligible executives defined pension benefits that supplement benefits under other retirement arrangements.  As of February 28, 2020, no active employees were participants in the SERP. During the thirteen weeks ended October 29, 2022, the Company did not make any cash contributions to the SERP and presently expects to pay approximately $1.2 million in benefits relating to the SERP during fiscal 2022.

The measurement date for the SERP is the fiscal year end, using actuarial techniques which reflect estimates for mortality, turnover and expected retirement. In addition, management makes assumptions concerning future salary increases. Discount rates are generally established as of the measurement date using theoretical bond models that select high-grade corporate bonds with maturities or coupons that correlate to the expected payouts of the applicable liabilities.

The following represents the components of the net periodic pension cost related to the Company’s SERP for the respective periods:

	Thirteen Weeks Ended				Thirty-nine Weeks Ended
(amounts in thousands)	October 29,		October 30,		October 29,		October 30,
	2022		2021		2022		2021
Interest cost	$	89	$	63	$	267	$	189
Net periodic pension cost	$	89	$	63	$	267	$	189

XML

Basic and Diluted Loss Per Share

9 Months Ended

Oct. 29, 2022

Basic and Diluted Loss Per Share [Abstract]

Basic and Diluted Loss Per Share

Note 12. Basic and Diluted Loss Per Share

Basic loss per share is calculated by dividing net loss by the weighted average common shares outstanding for the period. Diluted loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock (net of any assumed repurchases) that then shared in the earnings of the Company, if any.  It is computed by dividing net loss by the sum of the weighted average shares outstanding and additional common shares that would have been outstanding if the dilutive potential common shares had been issued for the Company’s common stock awards from the Company’s Stock Award Plans.

For the thirteen- and thirty-nine-week periods ended October 29, 2022 and October 30, 2021, the impact of all outstanding stock awards was not considered because the Company reported net losses in those periods and such impact would be anti-dilutive.  Accordingly, basic and diluted loss per share was the same. Total anti-dilutive stock awards for the thirteen and thirty-nine weeks ended October 29, 2022 were approximately 0.1 million shares.

For the thirteen-week and thirty-nine periods ended October 29, 2022, the impact of all outstanding warrants was not considered because the Company reported net losses in both periods and such impact would be anti-dilutive.  Accordingly, basic and diluted loss per share was the same. Total anti-dilutive warrants for the thirteen- and thirty -nine week periods ended October 29, 2022 were approximately 2.9 million shares.

XML

Income Taxes

9 Months Ended

Oct. 29, 2022

Income Taxes [Abstract]

Income Taxes

Note 13. Income Taxes

In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized.  The ultimate realization of deferred tax assets is dependent on the generation of future taxable income. Management considers the scheduled reversal of taxable temporary differences, projected future taxable income and tax planning strategies in making this assessment.  Based on available objective evidence, management concluded that a full valuation allowance should continue to be recorded against the Company’s deferred tax assets. Management will continue to assess the need for and amount of the valuation allowance against the deferred tax assets by considering all available evidence to the Company’s ability to generate future taxable income in its conclusion of the need for a full valuation allowance.  Any reversal of the Company’s valuation allowance will favorably impact its results of operations in the period of reversal.  The Company is currently unable to determine whether or when that reversal might occur, but it will continue to assess the realizability of its deferred tax assets and will adjust the valuation allowance if it is more likely than not that all or a portion of the deferred tax assets will become realizable in the future.  The Company has significant net operating loss carry forwards and other tax attributes that are available to offset projected taxable income and current taxes payable, if any, for the year ending January 29, 2022.  The deferred tax impact resulting from the utilization of the net operating loss carry forwards and other tax attributes will be offset by a reduction in the valuation allowance. As of January 29, 2022, the Company had a net operating loss carry forward of $352.7 million for federal income tax purposes and approximately $214.4 million for state income tax purposes that expire at various times through 2040 and are subject to certain limitations and statutory expiration periods.  The Company has not changed its overall conclusion with respect to the need for a valuation allowance against its net deferred tax assets, which remain fully reserved.

XML

Commitments and Contingencies

9 Months Ended

Oct. 29, 2022

Commitments and Contingencies [Abstract]

Commitments and Contingencies

Note 14. Commitments and Contingencies

Legal Proceedings

The Company is subject to legal proceedings and claims that have arisen in the ordinary course of its business and have not been finally adjudicated.  Although there can be no assurance as to the ultimate disposition of these matters, it is management’s opinion, based upon the information available at this time, that the expected outcome of these matters, individually and in the aggregate, will not have a material adverse effect on the results of operations and financial condition of the Company. As a result, the liability for the cases listed below is remote.

On June 18, 2021, Vijuve Inc. filed a lawsuit against Kaspien Inc. in the United States District Court for the Eastern District of Washington (Case No. 2:21-cv-00192-SAB) concerning a Retailer Agreement that the parties entered into in September of 2020. Vijuve manufactures skin care products and face massagers. The parties agreed that Kaspien would sell Vijuve’s products on Amazon. The complaint alleged that Kaspien breached the Retailer Agreement when it declined to acquiesce to Vijuve’s demand that Kaspien purchase over $700,000 of products. In total, Vijuve is seeking $774,000 in damages. Kaspien denies that it breached the agreement. Moreover, on July 19, 2021, Kaspien filed counterclaims and alleged that Vijuve breached the contract, including by refusing to buy back inventory from Kaspien upon termination of the Retailer Agreement.  Kaspien subsequently filed additional counterclaims against Vijuve for fraud and negligent misrepresentation. Kaspien is seeking at least $229,000 from Vijuve. A trial on all of the parties’ claims is scheduled for September 18, 2023. There is no determination of outcome, thus no contingencies are recognized as of the reporting date.

On February 17, 2022, CA Washington, LLC (“CA”) filed a lawsuit against Kaspien, Inc. in Wake County, North Carolina Superior Court (court file 22 CVS 2051). CA Washington, LLC claims that Kaspien, Inc. breached the contract between the parties by using CA’s technology platform to facilitate sales by third parties and by using CA’s technology to develop a competing platform. The lawsuit also includes an alternative claim for unjust enrichment and a claim for breach of North Carolina’s Unfair and Deceptive Trade Practices Act. CA seeks an unspecified amount of damages. Kaspien removed the lawsuit to federal court in the Eastern District of North Carolina (case number 5:22-cv-00111), filed an Answer denying CA’s claims, and asserted a counterclaim against CA for breach of contract and breach of the covenant of good faith and fair dealing. There is no determination of outcome, thus no contingencies are recognized as of the reporting date.

Contingent Value Rights

On March 30, 2020, the Company entered into the Contingent Value Rights Agreement (the “CVR Agreement”), pursuant to which the Related Party Entities received contingent value rights (“CVRs”) representing the contractual right to receive cash payments from the Company in an amount equal, in the aggregate, to 19.9% of the proceeds (10.35% for Alimco, 1.90% for Kick-Start, and 7.64% for RJHDC) received by the Company in respect of certain intercompany indebtedness owing to it by Kaspien and/or its equity interest in Kaspien. The Company does not anticipate these contingencies being met in Fiscal 2022.

On March 2, 2022, the Company entered into a Contingent Value Rights Agreement (the “Second CVR Agreement”) with the Tranche B Lender under the Subordinated Loan Agreement, pursuant to which the Tranche B Lender received contingent value rights (“Second CVRs”) representing the contractual right to receive cash payments from the Company in an amount equal, in the aggregate, to 9.0% of the proceeds received by the Company in respect of certain distributions by the Company or Kaspien; recapitalizations or financings of the Company or Kaspien (with appropriate carve out for trade financing in the ordinary course); repayment of intercompany indebtedness owing to the Company by Kaspien; or sale or transfer of any stock of the Company or Kaspien.

The CVRs terminate upon the earlier to occur of (i) certain consolidations, mergers or similar extraordinary events involving Kaspien (and, if applicable, the making of a cash payment by the Company to the Lenders pursuant to the CVR Agreement in connection therewith) and (ii) March 2, 2032.

XML

Nature of Operations (Policies)

9 Months Ended

Oct. 29, 2022

Nature of Operations [Abstract]

Nature of Operations

Kaspien Holdings Inc., which, together with its consolidated subsidiaries, is referred to herein as “Kaspien”, “the Company”, “we”, “us” and “our”, was incorporated in New York in 1972. We own 100% of the outstanding common stock of Kaspien Inc, through which our principal operations are conducted. Kaspien provides a platform of software and services to empower brands to grow their online distribution channels on digital marketplaces such as Amazon, Walmart, Target, eBay, among others. The Company helps brands achieve their online retail goals through its innovative and proprietary technology, tailored strategies, and mutually beneficial partnerships.

Kaspien provides a platform of software and services to empower brands to grow their online distribution channels on digital marketplaces such as Amazon, Walmart and Target, among others. The Company helps brands achieve their online retail goals through its innovative and proprietary technology, tailored strategies and mutually beneficial partnerships.

We are guided by 5 core principles:

• We are partner obsessed. Our customers are our partners. Every decision is focused on building mutually beneficial relationships that deliver results.

• We are insights driven. We make data actionable. Our curiosity drives us to discover opportunities early and often.

• We create simplicity. We challenge the status quo. We take the complicated and simplify it.

• We take ownership. We make things happen. We hold ourselves accountable and have a bias for action.

• We empower each other. We welcome and learn from diverse experiences. Our empathy ignites innovation and empowers meaningful change.

Liquidity and Cash Flows

Liquidity and Cash Flows:

The Company’s primary sources of liquidity are its borrowing capacity under its Credit Facility, available cash and cash equivalents, and to a lesser extent, cash generated from operations. Our cash requirements relate primarily to working capital needed to operate Kaspien, including funding operating expenses, the purchase of inventory and capital expenditures.

The Company incurred a net loss of $12.4 million and $2.2 million for the thirty-nine weeks ended October 29, 2022 and October 30, 2021, respectively.  The increase in the net loss was primarily attributable to a decrease in sales and gross margin. In addition, the Company has an accumulated deficit of $133.3 million as of October 29, 2022 and net cash used in operating activities for the thirty-nine weeks ended October 29, 2022 was $12.2 million. Net cash used in operating activities for the thirty-nine weeks ended October 30, 2021 was $10.0 million.

As disclosed in the Company’s Annual Report on Form 10-K filed April 29, 2022, the Company experienced negative cash flows from operations during fiscal 2021 and 2020 and we expect to incur net losses in fiscal 2022.

Our ability to achieve profitability and meet future liquidity needs and capital requirements will depend upon numerous factors, including the timing and amount of our revenue; the timing and amount of our operating expenses; the timing and costs of working capital needs; successful implementation of our strategy and planned activities; and our ability to overcome the impact of the COVID-19 pandemic. There can be no assurance that we will be successful in further implementing our business strategy or that the strategy, including the completed initiatives, will be successful in sustaining acceptable levels of sales growth and profitability. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.

The unaudited condensed consolidated financial statements for the thirteen and thirty-nine weeks ended October 29, 2022 were prepared pursuant to the rules and regulations of the Securities and Exchange Commission. The information furnished in these unaudited condensed consolidated financial statements reflects all normal, recurring adjustments which, in the opinion of management, are necessary for the fair presentation of such financial statements. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The ability of the Company to meet its liabilities and to continue as a going concern is dependent on improved profitability, the strategic initiatives for Kaspien and the availability of future funding. Based on recurring losses from operations, negative cash flows from operations, the expectation of continuing operating losses for the foreseeable future, and uncertainty with respect to any available future funding, the Company has concluded that there is substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

As of October 29, 2022, we had cash and cash equivalents of $0.8 million, net working capital of $18.0 million, and $9.5 in borrowings on our revolving credit facility, as further discussed below.

As of January 29, 2022, the Company had borrowings of $10.0 million under the Credit Facility. As of October 29, 2022 and October 30, 2021, the Company had no outstanding letters of credit. The Company had $5.2 million and $10.9 million available for borrowing under the Credit Facility as of October 29, 2022 and October 30, 2021, respectively.

On March 18, 2021, the Company closed an underwritten offering of 416,600 shares of common stock of the Company, at a price to the public of $32.50 per share. The gross proceeds of the offering were approximately $13.5 million, prior to deducting underwriting discounts and commissions and estimated offering expenses. The Company used the net proceeds from the offering for general corporate purposes, including working capital to implement its strategic plans, investments in technology to enhance its scalable platform and its core retail business.

Credit Facility

Credit Facility

On February 20, 2020, Kaspien Inc. entered into a Loan and Security Agreement (as subsequently amended, the “Loan Agreement”) with Eclipse Business Capital LLC (f/k/a Encina Business Credit, LLC) (“Eclipse”), as administrative agent, under which the lenders party thereto committed to provide up to $25 million in loans under a four-year, secured revolving credit facility (the “Credit Facility”).

On March 30, 2020, the Company and Kaspien Inc. (the “Loan Parties”) entered into Amendment No. 1 to the Loan Agreement (the “Amendment”). Pursuant to the Amendment, among other things, (i) the Company was added as “Parent” under the Amended Loan Agreement, (ii) the Company granted a first priority security interest in substantially all of the assets of the Company, including inventory, accounts receivable, cash and cash equivalents and certain other collateral, and (iii) the Loan Agreement was amended to (a) permit the incurrence of certain subordinated indebtedness under the Subordinated Loan Agreement (as defined below) and (b) limit the Company’s ability to incur additional indebtedness, create liens, make investments, make restricted payments or specified payments and merge or acquire assets.

On April 7, 2021, the Loan Parties entered into Amendment No. 2 to the Loan Agreement (the “Second Amendment”. Pursuant to the Second Amendment, the In-Transit Inventory Sublimit (as defined in the Loan Agreement) was increased from $2,000,000 to $2,500,000.

On September 17, 2021, the Loan Parties entered into Amendment No. 3 to the Loan Agreement (the “Third Amendment”). Pursuant to the Third Amendment, among other things, (i) the maturity of the Credit Facility has been extended to February 20, 2024, and the early termination fees have been accordingly reset; (ii) the LIBOR floor has been reduced to 1.00%; (iii) up to $4,000,000 of acquisitions are now allowed without Eclipse’s consent, subject to satisfaction of various conditions, including the Company having a trailing twelve month fixed charge coverage ratio of 1.20x and Excess Availability greater than the greater of (x) 20% of the average Borrowing Base for each 30 day period immediately prior to, and pro forma for, the purchase and (y) $1,500,000.

On March 2, 2022, the Loan Parties entered into Amendment No. 4 to the Loan Agreement (the “Fourth Amendment”). Pursuant to the Fourth Amendment, among other things, the Credit Facility was amended to permit the incurrence of the Additional Subordinated Loan (as defined below) under the Subordinated Loan Agreement (as defined below).

On November 1, 2022, the Loan Parties entered into Amendment No. 5 to the loan agreement (the “Fifth Amendment”). Pursuant to the Fifth Amendment, the Credit Facility was amended to replace LIBOR with the Secured Overnight Funding Rate (“SOFR”).

As of October 29, 2022 and October 30, 2021, the Company had borrowings of $9.5 and $5.9 million under the Credit Facility, respectively.

Subordinated Debt Agreement

On March 30, 2020, the Loan Parties entered into a Subordinated Loan and Security Agreement (the “Subordinated Loan Agreement”) with the lenders party thereto from time to time (the “Lenders”) and TWEC Loan Collateral Agent, LLC (the “Collateral Agent”), as collateral agent for the Lenders, pursuant to which the Lenders made a $5.2 million secured term loan (the “Subordinated Loan”) to Kaspien with a scheduled maturity date of May 22, 2023. As of October 29, 2022, unamortized debt issuance costs of $0.1 million are included in “Long Term Debt” on the unaudited condensed consolidated balance sheet.

Directors Jonathan Marcus, Thomas Simpson, and Michael Reickert are the chief executive officer of Alimco Re Ltd. (“Alimco”), the managing member of Kick-Start III, LLC and Kick-Start IV, LLC (“Kick-Start”), and a trustee of the Robert J. Higgins TWMC Trust (the “Trust”), an affiliate of RJHDC, LLC (“RJHDC” and together with Alimco and Kick-Start, “Related Party Entities”), respectively.  The Related Party Entities are parties to the Subordinated Loan Agreement.

Amendment No. 2 to Subordinated Loan and Security Agreement

On March 2, 2022, the Loan Parties entered into that certain Amendment No. 2 to Subordinated Loan and Security Agreement (“Amendment No. 2”) with the “Lenders and the Collateral Agent. Pursuant to Amendment No. 2, among other things, Alimco Re Ltd. (the “Tranche B Lender”) made an additional $5,000,000 secured term loan (the “Additional Subordinated Loan”) with a scheduled maturity date of March 31, 2024, which is the same maturity date as the existing loans under the Subordinated Loan Agreement.

Interest on the Additional Subordinated Loan accrues, subject to certain terms and conditions under the Subordinated Loan Agreement, at the rate of fifteen percent (15.0%) per annum, compounded on the last day of each calendar quarter by becoming a part of the principal amount of the Additional Subordinated Loan.

The Additional Subordinated Loan is also secured by a second priority security interest in substantially all of the assets of the Loan Parties, including inventory, accounts receivable, cash and cash equivalents and certain other collateral of the borrowers and guarantors under the Subordinated Loan Agreement. The Company will provide a limited guarantee of Kaspien’s obligations under the Additional Subordinated Loan.

Among other things, the Subordinated Loan Agreement limits the Loan Parties’ ability to incur additional indebtedness, create liens, make investments, make restricted payments or specified payments and merge or acquire assets.

The Subordinated Loan Agreement contains customary events of default, including, but not limited to, payment defaults, breaches of representations and warranties, covenant defaults, cross-defaults to other obligations, customary ERISA defaults, certain events of bankruptcy and insolvency, judgment defaults, the invalidity of liens on collateral, change in control, cessation of business or the liquidation of material assets of the borrowers and guarantors thereunder taken as a whole and the occurrence of an uninsured loss to a material portion of collateral.

The Loan Parties paid certain customary fees and expenses in connection with the Additional Subordinated Loan and Amendment No. 2.

Paycheck Protection Program

Paycheck Protection Program

On April 17, 2020, Kaspien received loan proceeds of $2.0 million (the “PPP Loan”) pursuant to the Paycheck Protection Program (“PPP”) under the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”). On June 14, 2021, the Small Business Administration (“SBA”) approved the Company’s application for forgiveness of the PPP Loan. The amount of the forgiveness was $1.9 million in principal and interest, which was the amount requested in the forgiveness application and was less than the original principal balance due of $2.0 million. Following the grant of forgiveness, an outstanding balance of $76,452 was paid during fiscal 2021.

In addition to the aforementioned current sources of existing working capital, the Company may explore certain other strategic alternatives that may become available to the Company, as well continuing our efforts to generate additional sales and increase margins. However, at this time the Company has no commitments to obtain any additional funds, and there can be no assurance such funds will be available on acceptable terms or at all, should we require such additional funds. If the Company is unable to improve its operations, it may be required to obtain additional funding, and the Company’s financial condition and results of operations may be materially adversely affected.

Furthermore, broad market and industry factors may seriously harm the market price of our common stock, regardless of our operating performance, and may adversely impact our ability to raise additional funds, should we require such additional funds.

Impact of COVID-19

Impact of COVID-19

The full extent to which the COVID-19 pandemic will continue to directly or indirectly impact our business, results of operations and financial condition, including expenses, reserves and allowances, and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19, including the actions taken to contain or treat it, as well as the economic impact on local, regional, national and international customers and markets, which are highly uncertain and cannot be predicted at this time. Our leadership team believes we have the necessary controls in place to mitigate these impacts.

XML

Recently Adopted Accounting Pronouncements (Policies)

9 Months Ended

Oct. 29, 2022

Recently Adopted Accounting Pronouncements [Abstract]

Recently Adopted Accounting Pronouncements

In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,” which introduced an expected credit loss model for the impairment of financial assets measured at amortized cost. The model replaces the probable, incurred loss model for those assets and instead, broadens the information an entity must consider in developing its expected credit loss estimate for assets measured at amortized cost. This standard will be effective for smaller reporting companies for fiscal years beginning after December 15, 2022, however early adoption is permitted. We are currently evaluating the impact of this new standard on the consolidated financial statements.

In March 2020, the FASB issued ASU No. 2020-04, “Reference Rate Reform (Topic 848): facilitation of the Effects of Reference Rate Reform on Financial Reporting” (“ASU 2020-04”). ASU 2020-04 provides optional expedients and exceptions for applying U.S. GAAP to contract modifications and hedging relationships that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. ASU 2020-04 provides, among other things, guidance that modifications of contracts within the scope of Topic 470, Debt, should be accounted for by prospectively adjusting the effective interest rate; modifications of contracts within the scope of Topic 840, Leases, should be accounted for as a continuation of the existing contract; and, changes in the critical terms of hedging relationships, caused by reference rate reform, should not result in the de-designation of the instrument, provided certain criteria are met. The Company’s exposure to LIBOR rates includes its credit facility. The amendments are effective as of March 12, 2020 through December 31, 2022. Adoption is permitted at any time. The Company is currently evaluating the impact this update will have on its Condensed Consolidated Financial Statements.

Recent accounting pronouncements pending adoption not discussed above are either not applicable or are not expected to have a material impact on our consolidated financial condition, results of operations, or cash flows.

XML

Intangible Assets (Tables)

9 Months Ended

Oct. 29, 2022

Intangible Assets [Abstract]

Amortization Expense of Intangible Assets

Amortization expense of intangible assets for the thirteen and thirty-nine weeks ended October 29, 2022 and October 30, 2021 consisted of the following:

	Thirteen Weeks Ended				Thirty-nine Weeks Ended
	October 29,		October 30,		October 29,		October 30,
(amounts in thousands)	2022		2021		2022		2021
Amortized intangible assets:
Technology	$	-	$	65	$	-	$	259
Trade names and trademarks		-		153		-		473
Total amortization expense	$	-	$	218	$	-	$	732

XML

Restricted Cash (Tables)

9 Months Ended

Oct. 29, 2022

Restricted Cash [Abstract]

Cash, Cash Equivalents and Restricted Cash

A summary of cash, cash equivalents and restricted cash is as follows (amounts in thousands):

	October 29,		January 29,		October 30,
	2022		2022		2021
Cash and cash equivalents	$	769	$	1,218	$	1,754
Restricted cash		2,759		3,605		3,890
Total cash, cash equivalents and restricted cash	$	3,528	$	4,823	$	5,644

XML

Stock Based Compensation (Tables)

9 Months Ended

Oct. 29, 2022

Stock Based Compensation [Abstract]

Stock Option Activity Under Stock Award Plans

The following table summarizes stock award activity during the thirteen weeks ended October 29, 2022:

	Employee Stock Award Plans
	Number of Shares Subject To Option			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term		Other Share Awards (1)			Weighted Average Grant Fair Value
Balance January 29, 2022		85,965		$	13.41		7.5		90,000		$	15.39
Granted		21,750			5.57		9.9		9,000			4.59
Forfeited		(20,045	)		9.31		9.1		(63,500	)		14.08
Canceled		(17,306	)		15.56		-		-			-
Exercised		-			-		-		(12,000	)		10.77
Balance October 29, 2022		70,364		$	10.23		7.6		23,500		$	17.69
Exercisable October 29, 2022		25,294		$	18.70		6.2		-		$	-

 ⁽¹⁾ Other Share Awards include restricted share units granted to employees and directors.

XML

Shareholders' Equity (Tables)

9 Months Ended

Oct. 29, 2022

Shareholders' Equity [Abstract]

Outstanding Warrants to Purchase Common Stock

The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company, all of which were exercisable, as of October 29, 2022:

Exercise		Number
Price		Outstanding
$	0.001		109,416
$	0.01		327,539
$	0.125		2,457,160
			2,894,115

XML

Defined Benefit Plan (Tables)

9 Months Ended

Oct. 29, 2022

Defined Benefit Plan [Abstract]

Net Periodic Benefit Cost

The following represents the components of the net periodic pension cost related to the Company’s SERP for the respective periods:

	Thirteen Weeks Ended				Thirty-nine Weeks Ended
(amounts in thousands)	October 29,		October 30,		October 29,		October 30,
	2022		2021		2022		2021
Interest cost	$	89	$	63	$	267	$	189
Net periodic pension cost	$	89	$	63	$	267	$	189

XML

Nature of Operations, Summary (Details)	9 Months Ended
	Oct. 29, 2022
Kaspien Inc. [Member]
Subsidiary Information [Abstract]
Ownership interest	100.00%

XML

Nature of Operations, Liquidity and Cash Flows (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended		9 Months Ended
	Mar. 18, 2021	Oct. 29, 2022	Oct. 30, 2021	Oct. 29, 2022	Oct. 30, 2021	Jan. 29, 2022
Liquidity and Cash Flows [Abstract]
Net loss		$ (3,561)	$ (886)	$ (12,407)	$ (2,221)
Accumulated deficit		(133,301)	(115,084)	(133,301)	(115,084)	$ (120,894)
Net cash used in operating activities				(12,194)	(9,990)
Cash and cash equivalents		769	1,754	769	1,754	1,218
Net working capital		18,000		18,000
Borrowings		9,494	5,858	9,494	5,858	9,966
Underwritten offering of common stock (in shares)	416,600
Share price (in dollars per share)	$ 32.5
Gross proceeds of offering	$ 13,500
Credit Facility [Member]
Liquidity and Cash Flows [Abstract]
Borrowings		9,500	5,900	9,500	5,900	$ 10,000
Outstanding letters of credit		0	0	0	0
Available borrowings		$ 5,200	$ 10,900	$ 5,200	$ 10,900

XML

Nature of Operations, Credit Facility and Subordinated Debt Agreement (Details)		9 Months Ended
	Sep. 17, 2021 USD ($)	Oct. 29, 2022 USD ($)	Mar. 02, 2022 USD ($)	Jan. 29, 2022 USD ($)	Oct. 30, 2021 USD ($)	Apr. 07, 2021 USD ($)	Apr. 06, 2021 USD ($)	Mar. 30, 2020 USD ($)	Feb. 20, 2020 USD ($)
Credit Facility [Abstract]
Short-term borrowings		$ 9,494,000		$ 9,966,000	$ 5,858,000
Subordinated Loan Agreement [Member]
Credit Facility [Abstract]
Maturity date		Mar. 31, 2024
Secured term loan			$ 5,000,000
Unamortized debt issuance costs		$ 100,000
Interest rate			15.00%
Kaspien Inc. [Member]
Credit Facility [Abstract]
Unamortized debt issuance costs		100,000
Kaspien Inc. [Member] | Subordinated Loan Agreement [Member]
Credit Facility [Abstract]
Secured term loan								$ 5,200,000
Credit Facility [Member]
Credit Facility [Abstract]
Short-term borrowings		$ 9,500,000		$ 10,000,000	$ 5,900,000
Credit Facility [Member] | Kaspien Inc. [Member]
Credit Facility [Abstract]
Loan amount						$ 2,500,000	$ 2,000,000
Term of loan		4 years
Maturity date		Feb. 20, 2024
Trailing period for fixed charge coverage ratio		12 months
Fixed charge coverage ratio	1.2
Percentage of average borrowing base for excess availability	20.00%
Period for borrowing base		30 days
Minimum excess availability amount	$ 1,500,000
Credit Facility [Member] | Kaspien Inc. [Member] | LIBOR [Member]
Credit Facility [Abstract]
Debt instrument, basis spread on variable rate	1.00%
Credit Facility [Member] | Maximum [Member] | Kaspien Inc. [Member]
Credit Facility [Abstract]
Loan amount									$ 25,000,000
Acquisitions value allowed without consent	$ 4,000,000
Credit Facility [Member] | Maximum [Member] | Kaspien Inc. [Member] | LIBOR [Member]
Credit Facility [Abstract]
Debt instrument, basis spread on variable rate		4.50%

XML

Nature of Operations, Paycheck Protection Program (Details) - USD ($)		9 Months Ended		12 Months Ended
	Jun. 14, 2021	Oct. 29, 2022	Oct. 30, 2021	Jan. 30, 2021	Apr. 17, 2020
CARES Act [Abstract]
Forgiveness of PPP Loan		$ 0	$ 1,963,000
COVID-19 [Member] | Paycheck Protection Program [Member]
CARES Act [Abstract]
Forgiveness of PPP Loan	$ 1,900,000
Payments of PPP loan				$ 76,452
COVID-19 [Member] | Kaspien Inc. [Member] | Paycheck Protection Program [Member]
CARES Act [Abstract]
Loan amount					$ 2,000,000
Forgiveness of PPP Loan	$ 1,900,000
Payments of PPP loan				$ 76,452

XML

Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 29, 2022	Oct. 30, 2021	Oct. 29, 2022	Oct. 30, 2021
Amortized Intangible Assets [Abstract]
Amortization expense	$ 0	$ 218	$ 0	$ 732
Technology [Member]
Amortized Intangible Assets [Abstract]
Amortization expense	0	65	0	259
Trade Names and Trademarks [Member]
Amortized Intangible Assets [Abstract]
Amortization expense	$ 0	$ 153	$ 0	$ 473

XML

Depreciation and Amortization (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 29, 2022	Oct. 30, 2021	Oct. 29, 2022	Oct. 30, 2021
Depreciation and Amortization [Abstract]
Depreciation and amortization	$ 0.4	$ 0.6	$ 1.0	$ 1.8

XML

Restricted Cash (Details) - USD ($) $ in Thousands	Oct. 29, 2022	Jan. 29, 2022	Oct. 30, 2021	Jan. 30, 2021
Restricted Cash and Cash Equivalents [Abstract]
Restricted cash, current asset	$ 1,158	$ 1,158	$ 1,158
Cash Equivalents and Restricted Cash [Abstract]
Cash and cash equivalents	769	1,218	1,754
Restricted cash	2,759	3,605	3,890
Total cash, cash equivalents and restricted cash	3,528	$ 4,823	$ 5,644	$ 6,555
Rabbi Trust [Member]
Restricted Cash and Cash Equivalents [Abstract]
Restricted cash, current asset	1,200
Restricted cash, long-term asset	1,600
Cash Equivalents and Restricted Cash [Abstract]
Restricted cash	$ 2,800

XML

Debt, Credit Facility (Details)		9 Months Ended
	Sep. 17, 2021 USD ($)	Oct. 29, 2022 USD ($)	Jan. 29, 2022 USD ($)	Oct. 30, 2021 USD ($)	Apr. 07, 2021 USD ($)	Apr. 06, 2021 USD ($)	Feb. 20, 2020 USD ($)
New Credit Facility [Abstract]
Short-term borrowings		$ 9,494,000	$ 9,966,000	$ 5,858,000
Other Assets [Member]
New Credit Facility [Abstract]
Unamortized debt issuance costs		100,000
Kaspien Inc. [Member]
New Credit Facility [Abstract]
Unamortized debt issuance costs		$ 100,000
New Credit Facility [Member] | Kaspien Inc. [Member]
New Credit Facility [Abstract]
Term of loan		4 years
New Credit Facility [Member] | Maximum [Member] | Kaspien Inc. [Member]
New Credit Facility [Abstract]
Loan amount							$ 25,000,000
Credit Facility [Member]
New Credit Facility [Abstract]
Short-term borrowings		$ 9,500,000	$ 10,000,000	$ 5,900,000
Credit Facility [Member] | Kaspien Inc. [Member]
New Credit Facility [Abstract]
Loan amount					$ 2,500,000	$ 2,000,000
Term of loan		4 years
Maturity date		Feb. 20, 2024
Trailing period for fixed charge coverage ratio		12 months
Fixed charge coverage ratio	1.2
Percentage of average borrowing base for excess availability	20.00%
Period for borrowing base		30 days
Minimum excess availability amount	$ 1,500,000
Credit Facility [Member] | Kaspien Inc. [Member] | LIBOR [Member]
New Credit Facility [Abstract]
Debt instrument, basis spread on variable rate	1.00%
Credit Facility [Member] | Minimum [Member] | Kaspien Inc. [Member] | LIBOR [Member]
New Credit Facility [Abstract]
Debt instrument, basis spread on variable rate		4.00%
Credit Facility [Member] | Minimum [Member] | Kaspien Inc. [Member] | Base Rate [Member]
New Credit Facility [Abstract]
Debt instrument, basis spread on variable rate		3.00%
Credit Facility [Member] | Maximum [Member] | Kaspien Inc. [Member]
New Credit Facility [Abstract]
Loan amount							25,000,000
Swing line loans							$ 5,000,000
Acquisitions value allowed without consent	$ 4,000,000
Credit Facility [Member] | Maximum [Member] | Kaspien Inc. [Member] | LIBOR [Member]
New Credit Facility [Abstract]
Debt instrument, basis spread on variable rate		4.50%
Credit Facility [Member] | Maximum [Member] | Kaspien Inc. [Member] | Base Rate [Member]
New Credit Facility [Abstract]
Debt instrument, basis spread on variable rate		3.50%

XML

Debt, Subordinated Loan Agreement (Details) - USD ($)	9 Months Ended
	Oct. 29, 2022	Mar. 02, 2022	Mar. 30, 2020
Subordinated Loan Agreement [Abstract]
Warrants issued to purchase common stock (in shares)	2,894,115
Kaspien Inc. [Member]
Subordinated Loan Agreement [Abstract]
Unamortized debt issuance costs	$ 100,000
Subordinated Loan [Member]
Subordinated Loan Agreement [Abstract]
Unamortized debt issuance costs	$ 200,000
Interest rate			12.00%
Warrants issued to purchase common stock (in shares)	244,532
Warrants exercise price (in dollars per share)	$ 0.01
Value of warrants	$ 700,000
Number of remaining outstanding warrants (in shares)	7,539
Subordinated Loan [Member] | Kaspien Inc. [Member]
Subordinated Loan Agreement [Abstract]
Secured term loan			$ 5,200,000
Maturity date	Mar. 31, 2024
Subordinated Loan [Member] | Alimco [Member]
Subordinated Loan Agreement [Abstract]
Warrants issued to purchase common stock (in shares)	127,208
Subordinated Loan [Member] | Kick-Start [Member]
Subordinated Loan Agreement [Abstract]
Warrants issued to purchase common stock (in shares)	23,401
Subordinated Loan [Member] | RJHDC [Member]
Subordinated Loan Agreement [Abstract]
Warrants issued to purchase common stock (in shares)	93,923
Additional Subordinated Loan [Member]
Subordinated Loan Agreement [Abstract]
Secured term loan		$ 5,000,000
Unamortized debt issuance costs	$ 1,100,000
Interest rate		15.00%
Warrants issued to purchase common stock (in shares)		320,000
Warrants exercise price (in dollars per share)		$ 0.01
Value of warrants		$ 1,600,000
Additional Subordinated Loan [Member] | Kaspien Inc. [Member]
Subordinated Loan Agreement [Abstract]
Maturity date	Mar. 31, 2024

XML

Debt, Paycheck Protection Program (Details) - USD ($)		9 Months Ended		12 Months Ended
	Jun. 14, 2021	Oct. 29, 2022	Oct. 30, 2021	Jan. 30, 2021	Apr. 17, 2020
CARES Act [Abstract]
Forgiveness of PPP Loan		$ 0	$ 1,963,000
COVID-19 [Member] | Paycheck Protection Program [Member]
CARES Act [Abstract]
Forgiveness of PPP Loan	$ 1,900,000
Payments of PPP loan				$ 76,452
COVID-19 [Member] | Kaspien [Member] | Paycheck Protection Program [Member]
CARES Act [Abstract]
Loan amount					$ 2,000,000

XML

Stock Based Compensation (Details)		9 Months Ended	12 Months Ended
		Oct. 29, 2022 USD ($) Plan $ / shares shares	Jan. 29, 2022 $ / shares shares
Stock Awards [Abstract]
Number of employee stock award plans | Plan		3
Weighted Average Grant Fair Value [Abstract]
Intrinsic value of stock awards outstanding | $		$ 0
Intrinsic value of stock awards exercisable | $		$ 0
Employee Stock Award Plans [Member]
Number of Shares Subject to Option [Roll Forward]
Balance (in shares)		85,965
Granted (in shares)		21,750
Forfeited (in shares)		(20,045)
Canceled (in shares)		(17,306)
Exercised (in shares)		0
Balance (in shares)		70,364	85,965
Exercisable (in shares)		25,294
Weighted Average Exercise Price [Abstract]
Balance (in dollars per share) | $ / shares		$ 13.41
Granted (in dollars per share) | $ / shares		5.57
Forfeited (in dollars per share) | $ / shares		9.31
Canceled (in dollars per share) | $ / shares		15.56
Exercised (in dollars per share) | $ / shares		0
Balance (in dollars per share) | $ / shares		10.23	$ 13.41
Exercisable (in dollars per share) | $ / shares		$ 18.7
Weighted Average Remaining Contractual Term [Abstract]
Weighted average remaining contractual term		7 years 7 months 6 days	7 years 6 months
Granted		9 years 10 months 24 days
Forfeited		9 years 1 month 6 days
Exercisable		6 years 2 months 12 days
Other Share Awards [Abstract]
Balance (in shares)	[1]	90,000
Granted (in shares)	[1]	9,000
Forfeited (in shares)	[1]	(63,500)
Cancelled (in shares)	[1]	0
Exercised (in shares)	[1]	(12,000)
Balance (in shares)	[1]	23,500	90,000
Exercisable (in shares)	[1]	0
Weighted Average Grant Fair Value [Abstract]
Balance (in dollars per share) | $ / shares		$ 15.39
Granted (in dollars per share) | $ / shares		4.59
Forfeited (in dollars per share) | $ / shares		14.08
Canceled (in dollars per share) | $ / shares		0
Exercised (in dollars per share) | $ / shares		10.77
Balance (in dollars per share) | $ / shares		17.69	$ 15.39
Exercisable (in dollars per share) | $ / shares		$ 0
New Plan [Member]
Stock Awards [Abstract]
Equity awards authorized for issuance (in shares)		500,000
Equity awards granted and are outstanding (in shares)		70,364
Equity awards vested and exercisable (in shares)		25,294
Shares available for future grants (in shares)		497,000

[1] Other Share Awards include restricted share units granted to employees and directors.

XML

Shareholders' Equity (Details) - USD ($) $ / shares in Units, $ in Millions		9 Months Ended
	Jul. 12, 2022	Oct. 29, 2022	Mar. 18, 2021
Shareholders' Equity [Abstract]
Share price (in dollars per share)			$ 32.5
Proceeds from equity		$ 7.1
Offering expenses		$ 0.9
Outstanding Warrants to Purchase Common Stock [Abstract]
Number Outstanding (in shares)		2,894,115
PIPE Purchase Agreement [Member]
Shareholders' Equity [Abstract]
Proceeds from issuance of private placement	$ 6.0
Outstanding Warrants to Purchase Common Stock [Abstract]
Exercise Price (in dollars per share)		$ 0.01
Number Outstanding (in shares)		327,539
PIPE Purchase Agreement [Member] | Pre-Funded Warrants [Member]
Shareholders' Equity [Abstract]
Warrant exercisable (in shares)	1
Outstanding Warrants to Purchase Common Stock [Abstract]
Exercise Price (in dollars per share)		$ 0.001
Number Outstanding (in shares)	1,818,182	109,416
PIPE Purchase Agreement [Member] | Investor Warrants [Member]
Shareholders' Equity [Abstract]
Warrant exercisable (in shares)	1
Share price (in dollars per share)	$ 3.3
Warrants exercise price (in dollars per share)	$ 3.13
Warrants expiration period		5 years
Outstanding Warrants to Purchase Common Stock [Abstract]
Exercise Price (in dollars per share)		$ 0.125
Number Outstanding (in shares)		2,457,160
Registered Purchase Agreement [Member]
Shareholders' Equity [Abstract]
Proceeds from equity	$ 2.0
Registered Purchase Agreement [Member] | Pre-Funded Warrants [Member]
Shareholders' Equity [Abstract]
Warrant exercisable (in shares)	1
Outstanding Warrants to Purchase Common Stock [Abstract]
Exercise Price (in dollars per share)	$ 0.001
Number Outstanding (in shares)	638,978

XML

Defined Benefit Plan (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 29, 2022	Oct. 30, 2021	Oct. 29, 2022	Oct. 30, 2021
Net Periodic Pension Cost [Abstract]
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Interest Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]			Interest Income (Expense), Net
Supplemental Executive Retirement Plan [Member]
Contributions by Employer [Abstract]
Cash contributions by employer	$ 0
Expected cash contributions by employer	1,200		$ 1,200
Net Periodic Pension Cost [Abstract]
Interest cost	89	$ 63	267	$ 189
Net periodic pension cost	$ 89	$ 63	$ 267	$ 189

XML

Basic and Diluted Loss Per Share (Details) - shares shares in Millions	3 Months Ended	9 Months Ended
	Oct. 29, 2022	Oct. 29, 2022
Basic and Diluted Loss Per Share [Abstract]
Total anti-dilutive stock awards (in shares)	0.1	0.1
Warrants [Member]
Basic and Diluted Loss Per Share [Abstract]
Total anti-dilutive stock awards (in shares)	2.9	2.9

XML

Income Taxes (Details) - USD ($) $ in Millions	9 Months Ended
	Oct. 29, 2022	Jan. 29, 2022
Federal [Member]
Operating Loss Carryforwards Components [Abstract]
Net operating loss carryforwards		$ 352.7
Operating loss carryforward expiration year	2040
State [Member]
Operating Loss Carryforwards Components [Abstract]
Net operating loss carryforwards		$ 214.4
Operating loss carryforward expiration year	2040

XML

Commitments and Contingencies (Details) - USD ($)	Jul. 19, 2021	Jun. 18, 2021	Mar. 02, 2022	Mar. 30, 2020
Legal Proceedings [Abstract]
Percentage of CVR to receive cash payment			9.00%	19.90%
Alimco [Member]
Legal Proceedings [Abstract]
Percentage of CVR to receive cash payment				10.35%
Kick-Start [Member]
Legal Proceedings [Abstract]
Percentage of CVR to receive cash payment				1.90%
RJHDC [Member]
Legal Proceedings [Abstract]
Percentage of CVR to receive cash payment				7.64%
Vijuve Inc. [Member]
Legal Proceedings [Abstract]
Purchase of product expected as part of agreement		$ 700,000
Damages sought value		$ 774,000
Vijuve Inc. [Member] | Minimum [Member]
Legal Proceedings [Abstract]
Damages claims value	$ 229,000